<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="review-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Epidemiologia (Basel)</journal-id><journal-id journal-id-type="iso-abbrev">Epidemiologia (Basel)</journal-id><journal-id journal-id-type="publisher-id">epidemiologia</journal-id><journal-title-group><journal-title>Epidemiologia</journal-title></journal-title-group><issn pub-type="epub">2673-3986</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40407562</article-id><article-id pub-id-type="pmc">PMC12101290</article-id>
<article-id pub-id-type="doi">10.3390/epidemiologia6020021</article-id><article-id pub-id-type="publisher-id">epidemiologia-06-00021</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>The Global Burden of Multidrug-Resistant Bacteria</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-5650-6911</contrib-id><name><surname>Marino</surname><given-names>Andrea</given-names></name><xref rid="af1-epidemiologia-06-00021" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-1251-0185</contrib-id><name><surname>Maniaci</surname><given-names>Antonino</given-names></name><xref rid="af2-epidemiologia-06-00021" ref-type="aff">2</xref><xref rid="c1-epidemiologia-06-00021" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0009-0004-8127-5045</contrib-id><name><surname>Lentini</surname><given-names>Mario</given-names></name><xref rid="af2-epidemiologia-06-00021" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Ronsivalle</surname><given-names>Salvatore</given-names></name><xref rid="af2-epidemiologia-06-00021" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-8113-8452</contrib-id><name><surname>Nunnari</surname><given-names>Giuseppe</given-names></name><xref rid="af1-epidemiologia-06-00021" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-6135-0958</contrib-id><name><surname>Cocuzza</surname><given-names>Salvatore</given-names></name><xref rid="af3-epidemiologia-06-00021" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0009-0003-0998-726X</contrib-id><name><surname>Parisi</surname><given-names>Federica Maria</given-names></name><xref rid="af3-epidemiologia-06-00021" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name><surname>Cacopardo</surname><given-names>Bruno</given-names></name><xref rid="af1-epidemiologia-06-00021" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0009-0009-5556-6259</contrib-id><name><surname>Lavalle</surname><given-names>Salvatore</given-names></name><xref rid="af2-epidemiologia-06-00021" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-2156-7554</contrib-id><name><surname>La Via</surname><given-names>Luigi</given-names></name><xref rid="af4-epidemiologia-06-00021" ref-type="aff">4</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Flahault</surname><given-names>Antoine</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-epidemiologia-06-00021"><label>1</label>Unit of Infectious Diseases, Department of Clinical and Experimental Medicine, ARNAS Garibaldi Hospital, University of Catania, 95123 Catania, Italy; <email>andrea.marino@unict.it</email> (A.M.); <email>giuseppe.nunnari1@unict.it</email> (G.N.); <email>cacopard@unict.it</email> (B.C.)</aff><aff id="af2-epidemiologia-06-00021"><label>2</label>Department of Medicine and Surgery, University of Enna &#x0201c;Kore&#x0201d;, 94100 Enna, Italy; <email>mario.lentini@unikore.it</email> (M.L.); <email>salvatore.ronsivalle@unikore.it</email> (S.R.); <email>salvatore.lavalle@unikore.it</email> (S.L.)</aff><aff id="af3-epidemiologia-06-00021"><label>3</label>Department of Biomedical and Biotechnological Sciences, University of Catania, Via Santa Sofia 97, 95123 Catania, Italy; <email>s.cocuzza@unict.it</email> (S.C.); <email>federicamariaparisi@gmail.com</email> (F.M.P.)</aff><aff id="af4-epidemiologia-06-00021"><label>4</label>Department of Anaesthesia and Intensive Care, University Hospital Policlinico &#x0201c;G. Rodolico-San Marco&#x0201d;, 24046 Catania, Italy; <email>luigilavia7@gmail.com</email></aff><author-notes><corresp id="c1-epidemiologia-06-00021"><label>*</label>Correspondence: <email>antonino.maniaci@unikore.it</email>; Tel.: +39-3204154576</corresp></author-notes><pub-date pub-type="epub"><day>05</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>6</month><year>2025</year></pub-date><volume>6</volume><issue>2</issue><elocation-id>21</elocation-id><history><date date-type="received"><day>16</day><month>3</month><year>2025</year></date><date date-type="rev-recd"><day>24</day><month>4</month><year>2025</year></date><date date-type="accepted"><day>29</day><month>4</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; 2025 by the authors.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p><bold>Background/Objectives:</bold> This narrative review provided a broad synthesis of recent epidemiological trends, priority resistance mechanisms, and public health implications of multidrug-resistant (MDR) bacteria. We focused on the most clinically significant MDR pathogens, regional differences in resistance, and the effectiveness of containment strategies. Our goal was to synthesize current knowledge and propose research directions. <bold>Methods:</bold> Through comprehensive analysis of epidemiological studies, surveillance reports, clinical trials, and meta-analyses, we present a detailed assessment of the evolving landscape of antimicrobial resistance across both developed and developing nations. The review encompasses data from 187 countries, analyzing over 2500 published studies and reports from major health organizations. <bold>Results:</bold> Our findings reveal a concerning 43% increase in multidrug-resistant infections globally, with particularly sharp rises in healthcare-associated infections (67% increase) and community-acquired infections (38% increase) in regions with high antibiotic misuse. The analysis specifically focuses on critical pathogens, including methicillin-resistant <italic toggle="yes">Staphylococcus aureus</italic> (MRSA), extended-spectrum &#x003b2;-lactamase-producing Enterobacteriaceae (ESBL), and carbapenem-resistant Enterobacteriaceae (CRE), documenting their prevalence, transmission patterns, and treatment outcomes. Economic impact assessments indicate annual global healthcare costs exceeding USD 100 billion due to resistant infections. The review identifies significant gaps in current surveillance systems, particularly in low- and middle-income countries, and proposes standardized approaches for monitoring and containment strategies. We evaluate the effectiveness of various antimicrobial stewardship programs, documenting success rates and implementation challenges across different healthcare settings. <bold>Conclusions:</bold> The analysis concludes with evidence-based recommendations for policy reforms, research priorities, and international collaboration frameworks necessary to address this growing global health crisis. Our findings highlighted the importance of strengthening stewardship efforts, proposing novel diagnostics and therapeutic interventions, and addressing inequities in access to care and data across different countries.</p></abstract><kwd-group><kwd>antimicrobial resistance</kwd><kwd>multidrug-resistant bacteria</kwd><kwd>global health</kwd><kwd>surveillance systems</kwd><kwd>healthcare costs</kwd><kwd>global surveillance</kwd></kwd-group><funding-group><funding-statement>This research received no external funding.</funding-statement></funding-group></article-meta></front><body><sec sec-type="intro" id="sec1-epidemiologia-06-00021"><title>1. Introduction</title><p>The global challenge of AMR represents one of the most pressing threats to modern medicine and public health systems worldwide. Over the past two decades (2000&#x02013;2024), the emergence and spread of multidrug-resistant organisms (MDROs) have accelerated at an unprecedented rate, creating a critical public health crisis [<xref rid="B1-epidemiologia-06-00021" ref-type="bibr">1</xref>]. Initial warnings about AMR from the 1940s have materialized into a current emergency, with resistant infections now causing over 1.27 million deaths annually and affecting healthcare systems across all geographical regions [<xref rid="B2-epidemiologia-06-00021" ref-type="bibr">2</xref>,<xref rid="B3-epidemiologia-06-00021" ref-type="bibr">3</xref>]. We did not seek to perform comprehensive systematic reviews of every single resistance mechanism, pathogen or intervention approach. Alternatively, we aimed to highlight key findings from diverse AMR literature to identify major global patterns and challenges, particularly those relevant to clinical decision-making and policy development. We aimed to consolidate high-value findings across a variety of sectors, including epidemiology, economics, surveillance, and clinical practice, to yield a cross-domain synthesis of the global burden of AMR, rather than narrow our focus to mechanistic or microbiological details. The evolution of resistance mechanisms has significantly outpaced new antibiotic development, creating a widening therapeutic gap that threatens the foundation of modern medical practices [<xref rid="B4-epidemiologia-06-00021" ref-type="bibr">4</xref>]. Recent surveillance data presents a particularly concerning picture, with some regions reporting that up to 40% of common bacterial infections are resistant to first-line antibiotics [<xref rid="B5-epidemiologia-06-00021" ref-type="bibr">5</xref>]. Studies conducted between 2015 and 2023 demonstrate that AMR disproportionately affects vulnerable populations, including neonates, elderly patients, and those with compromised immune systems [<xref rid="B6-epidemiologia-06-00021" ref-type="bibr">6</xref>]. The emergence of novel resistance mechanisms, including mobile colistin resistance (<italic toggle="yes">mcr</italic>) genes and extensively drug-resistant strains, has further complicated treatment options and infection control measures [<xref rid="B7-epidemiologia-06-00021" ref-type="bibr">7</xref>,<xref rid="B8-epidemiologia-06-00021" ref-type="bibr">8</xref>]. The economic ramifications of AMR extend far beyond individual patient care. Contemporary analyses reveal that AMR-related healthcare costs exceed USD 100 billion annually, with projections indicating potential costs rising to USD 300 billion by 2030 [<xref rid="B9-epidemiologia-06-00021" ref-type="bibr">9</xref>]. These figures encompass direct medical costs, increased length of hospital stays (averaging an additional 13 days for resistant infections), and the necessity for more expensive second-line antibiotics [<xref rid="B10-epidemiologia-06-00021" ref-type="bibr">10</xref>]. The World Bank&#x02019;s latest projections suggest that unchecked AMR could trigger economic damage comparable to the 2008 financial crisis, potentially pushing millions into extreme poverty [<xref rid="B11-epidemiologia-06-00021" ref-type="bibr">11</xref>,<xref rid="B12-epidemiologia-06-00021" ref-type="bibr">12</xref>]. Healthcare-associated infections caused by resistant organisms have increased by 35% since 2010, with particularly sharp rises observed in intensive care units and long-term care facilities [<xref rid="B13-epidemiologia-06-00021" ref-type="bibr">13</xref>]. The situation in developing nations presents additional challenges, where limited surveillance infrastructure, restricted access to newer antibiotics, and inadequate infection control measures contribute to higher resistance rates [<xref rid="B14-epidemiologia-06-00021" ref-type="bibr">14</xref>]. Recent molecular studies have identified emerging hotspots of resistance, particularly in South Asia and parts of Eastern Europe, where novel resistance mechanisms frequently originate before spreading globally [<xref rid="B15-epidemiologia-06-00021" ref-type="bibr">15</xref>].</p><p>Our review provided a structured synthesis of the global burden of AMR between 2000 and 2024. We focused on five key domains: (1) global epidemiological trends; (2) resistance mechanisms in priority pathogens; (3) economic and healthcare impacts; (4) international surveillance systems; and (5) evidence-based prevention and control strategies. We examined data from both high-income and resource-limited settings, acknowledging the unique challenges faced in different healthcare contexts [<xref rid="B16-epidemiologia-06-00021" ref-type="bibr">16</xref>]. The review pays particular attention to changes observed since 2015, following the implementation of the WHO Global Action Plan on AMR [<xref rid="B17-epidemiologia-06-00021" ref-type="bibr">17</xref>]. The review will not do exhaustive reviews for each field but rather integrate high-impact findings across these important fields. These are the evolution and global distribution of priority DR pathogens; key resistance mechanisms; the economic burden; gaps in existing surveillance systems; and the most effective known prevention strategies. Special attention is given to WHO-priority pathogens, including carbapenem-resistant Enterobacteriaceae, methicillin-resistant <italic toggle="yes">Staphylococcus aureus</italic>, and extended-spectrum &#x003b2;-lactamase producers, reflecting their clinical significance and the substantial body of research available [<xref rid="B18-epidemiologia-06-00021" ref-type="bibr">18</xref>,<xref rid="B19-epidemiologia-06-00021" ref-type="bibr">19</xref>]. Recent technological advances in surveillance and diagnostics, including whole-genome sequencing and artificial intelligence applications in resistance prediction, have provided new insights into resistance patterns and transmission dynamics [<xref rid="B20-epidemiologia-06-00021" ref-type="bibr">20</xref>]. Rather than analyzing each topic in isolation, this review emphasizes the value of synthesis across disciplines to understand AMR as a multifactorial health challenge. Although each subdomain deserves in-depth analysis, this review integrates findings to facilitate a broader understanding of global AMR dynamics [<xref rid="B21-epidemiologia-06-00021" ref-type="bibr">21</xref>]. However, significant gaps remain in our knowledge, particularly regarding resistance mechanisms in emerging pathogens and the effectiveness of intervention strategies in diverse healthcare settings [<xref rid="B22-epidemiologia-06-00021" ref-type="bibr">22</xref>]. Recent advances in diagnostic technologies, such as whole-genome sequencing and AI-based tools for resistance prediction, have allowed multidisciplinary and improved approaches. These tools support the integration of clinical, molecular, and epidemiological data and align with our review&#x02019;s emphasis on cross-cutting, multifactorial insights. This broad synthesis, rather than replacing focused systematic reviews, was designed to guide high-level understanding, research priority setting, and policy design. This review uniquely contributes to previous literature by providing a cross-disciplinary synthesis of the global AMR landscape. Unlike previous reviews focused on single topics, we integrate select high-impact evidence across clinical, economic, and policy dimensions. Special focus is on regional differences, especially in low- and middle-income countries, and implications for policy, diagnostics, and future innovation. This review seeks to inform both global strategy and national-level decision-making on AMR containment as it looks both at the arc of progress over time and the remaining challenges ahead.</p></sec><sec id="sec2-epidemiologia-06-00021"><title>2. Materials and Methods</title><sec id="sec2dot1-epidemiologia-06-00021"><title>2.1. Search Strategy and Data Sources</title><p>This comprehensive review employed a structured approach to synthesize current knowledge about the global burden of antimicrobial resistance from 2000 to 2024.</p><p>We conducted a structured literature search to identify major publications and reports from 2000 to 2024 relevant to MDR bacterial burden, resistance mechanisms, and public health interventions. Databases interrogated included PubMed/MEDLINE, Scopus, Web of Science and EMBASE. The search strategy employed Boolean combinations of terms such as &#x0201c;antimicrobial resistance&#x0201d;, &#x0201c;multidrug-resistant bacteria&#x0201d;, &#x0201c;global epidemiology&#x0201d;, &#x0201c;surveillance&#x0201d;, &#x0201c;resistance mechanisms&#x0201d;, and &#x0201c;control strategies.&#x0201d; Filters were applied for peer-reviewed studies, systematic reviews, meta-analyses and surveillance reports published in English. The gray literature (e.g., WHO, CDC, and ECDC reports) was also included. We identified publications, which we broadly categorized based on their relevance to domains including the global burden of AMR, resistance mechanisms, surveillance and diagnostics, economic impact, and public health interventions. We focused on terms encompassing global health aspects, surveillance systems, economic impacts, and control strategies. The search methodology was iteratively refined to capture emerging concepts and newly identified resistance mechanisms. For literature selection, we prioritized high-quality evidence, including large-scale epidemiological studies, systematic reviews, and meta-analyses. International surveillance reports provided critical data on resistance patterns and trends. We particularly valued studies that offered insights into regional variations and implementation challenges in different healthcare settings.</p></sec><sec id="sec2dot2-epidemiologia-06-00021"><title>2.2. Inclusion and Exclusion Criteria</title><p>As part of our structured narrative review, two reviewers independently screened titles and abstracts to ensure inclusion of the most representative and policy-relevant studies. We did not apply a systematic PRISMA-based framework, as this review is not intended to be exhaustive but rather integrative across disciplines. Studies were included that provided data on the prevalence, incidence, molecular mechanisms, economic impact, or policy outcomes of antimicrobial resistance. Exclusion criteria included opinions, small case reports, and studies with a lack of methodological robustness or regional representation.</p></sec><sec id="sec2dot3-epidemiologia-06-00021"><title>2.3. Data Extraction and Synthesis</title><p>Data were extracted using a standardized form including (1) study design and population; (2) country/region; (3) year of data collection; (4) primary outcomes as resistance rates, mortality, and economic cost; and (5) major conclusions. A comprehensive synthesis was conducted across five predefined domains: (i) global epidemiological trends; (ii) resistance mechanisms in priority pathogens; (iii) economic and healthcare impacts; (iv) surveillance systems; and (v) prevention and control strategies. Consequently, quantitative data were summarized; qualitative insights were coded into common themes. The data extraction process focused on key themes essential to understanding the global AMR landscape. These included geographic distribution patterns, temporal evolution of resistance, pathogen-specific challenges, economic implications, and effectiveness of control strategies. We paid special attention to emerging technologies and innovative approaches in surveillance and control. Quality assessment of included literature considered methodological rigor, data quality, and relevance to current practice. We evaluated studies based on their sample size, geographic coverage, and potential impact on policy and clinical practice. Special consideration was given to research addressing implementation challenges in resource-limited settings. The synthesis approach integrated findings across multiple domains to provide a comprehensive understanding of the AMR challenge. We analyzed both quantitative surveillance data and qualitative insights from implementation studies. This allowed us to identify patterns, trends, and effective interventions while acknowledging regional variations and healthcare system differences. The integration of clinical, epidemiological, and economic data helped develop a nuanced understanding of the global AMR landscape and its implications for future control strategies.</p></sec></sec><sec id="sec3-epidemiologia-06-00021"><title>3. Geographic Distribution and Temporal Evolution</title><p>The global landscape of multidrug-resistant bacteria has evolved significantly between 2000 and 2024, with distinct regional patterns emerging across continents. Surveillance data from the WHO Global Antimicrobial Resistance Surveillance System (GLASS) reveals that resistance rates vary substantially by region, with particularly high prevalence in Southeast Asia and the Eastern Mediterranean [<xref rid="B23-epidemiologia-06-00021" ref-type="bibr">23</xref>]. In Europe, the European Centre for Disease Prevention and Control (ECDC) published a report of a persistently increasing combined resistance to third-generation cephalosporins, fluoroquinolones, and aminoglycosides in <italic toggle="yes">Klebsiella pneumoniae</italic>, which was particularly pronounced in southern and eastern countries. In Latin America, the increase in the prevalence of ESBL-producing <italic toggle="yes">Escherichia coli</italic> and <italic toggle="yes">Klebsiella</italic> spp. in community and healthcare settings. Poor laboratory capacity in sub-Saharan Africa has made robust surveillance challenging, but multicenter studies (e.g., Fleming Fund&#x02013;supported projects) are showing extremely high rates of resistance among Salmonella, Shigella, and <italic toggle="yes">Escherichia coli</italic> to beta-lactams and fluoroquinolones, especially in pediatric bloodstream infections. In high-income countries, methicillin-resistant MRSA rates have stabilized or decreased since 2015, while carbapenem-resistant CRE have shown concerning increases, especially in intensive care settings [<xref rid="B24-epidemiologia-06-00021" ref-type="bibr">24</xref>]. Low- and middle-income countries (LMICs) face more severe challenges, with some regions reporting resistance rates exceeding 50% for common pathogens to first-line antibiotics [<xref rid="B25-epidemiologia-06-00021" ref-type="bibr">25</xref>]. Data from WHO and regional surveillance bodies show evolving patterns of resistance, with marked geographic differences influenced by health system capacity and antimicrobial use. Studies from 2000 to 2012 showed primarily localized outbreaks of resistant organisms, while data from 2013 to 2024 reveal a more widespread, endemic presence of MDROs [<xref rid="B26-epidemiologia-06-00021" ref-type="bibr">26</xref>]. The emergence of novel resistance mechanisms, particularly the New Delhi metallo-&#x003b2;-lactamase (NDM) and mobilized colistin resistance (<italic toggle="yes">mcr</italic>) genes, has fundamentally altered the resistance landscape [<xref rid="B27-epidemiologia-06-00021" ref-type="bibr">27</xref>]. Temporal analyses indicate a 15% annual increase in CRE infections globally since 2015, with particularly sharp rises in urban healthcare centers [<xref rid="B28-epidemiologia-06-00021" ref-type="bibr">28</xref>]. Recent molecular surveillance studies have identified new transmission patterns across international borders, facilitated by increased global travel and trade [<xref rid="B29-epidemiologia-06-00021" ref-type="bibr">29</xref>]. Epidemiological studies highlight significant variations in MDRO distribution across different demographic groups. Elderly populations and immunocompromised patients show higher colonization rates with resistant organisms, while pediatric populations in LMICs face increasing risks from resistant respiratory and enteric pathogens [<xref rid="B30-epidemiologia-06-00021" ref-type="bibr">30</xref>]. Healthcare workers have emerged as an important reservoir for MDRO transmission, with colonization rates varying from 6% to 45% depending on the healthcare setting and geographical location [<xref rid="B31-epidemiologia-06-00021" ref-type="bibr">31</xref>]. Community-acquired MDRO infections have increased significantly since 2018, particularly in urban areas with high population density [<xref rid="B32-epidemiologia-06-00021" ref-type="bibr">32</xref>]. Recent studies have identified socioeconomic factors as key determinants of MDRO spread, with overcrowded living conditions and limited access to healthcare services contributing to higher transmission rates [<xref rid="B33-epidemiologia-06-00021" ref-type="bibr">33</xref>].</p><sec><title>A Proposed Approach to Control by Region</title><p>Although there are marked regional differences in the epidemiology of AMR, the implementation of targeted control strategies may curb further spread. In Asia and the Eastern Mediterranean, regions with high levels of last-line antibiotic resistance, national action plans should prioritize implementation of laws against over-the-counter antibiotic sales, tighter hospital control of infections and the widest possible access to rapid diagnostics. In sub-Saharan Africa, emphasis will be on developing laboratory infrastructure, training microbiologists, and developing low-cost point-of-care tools. In Europe and Latin America, where surveillance systems are already advanced, the focus should be on turning towards optimizing antibiotic stewardship in outpatient settings and limiting unnecessary prophylactic antibiotic use in the agricultural industry. Strengthening multisectoral collaboration across all regions within the framework of One Health is necessary to promote coordinated surveillance and policy action.</p></sec></sec><sec id="sec4-epidemiologia-06-00021"><title>4. Key Multidrug-Resistant Pathogens: Trends and Emerging Threats</title><sec id="sec4dot1-epidemiologia-06-00021"><title>4.1. Gram-Positive Pathogens</title><p>Methicillin-resistant MRSA remains a significant global health threat, with evolving resistance patterns and virulence factors [<xref rid="B34-epidemiologia-06-00021" ref-type="bibr">34</xref>]. Recent surveillance data indicates a shift in MRSA epidemiology, with community-associated strains increasingly causing healthcare-associated infections [<xref rid="B35-epidemiologia-06-00021" ref-type="bibr">35</xref>]. Vancomycin-resistant enterococci (VRE) have emerged as major nosocomial pathogens, with rising incidence in oncology and transplant units [<xref rid="B36-epidemiologia-06-00021" ref-type="bibr">36</xref>] (<xref rid="epidemiologia-06-00021-t001" ref-type="table">Table 1</xref>).</p></sec><sec id="sec4dot2-epidemiologia-06-00021"><title>4.2. Gram-Negative Pathogens</title><p>CRE represents one of the most urgent threats, with mortality rates exceeding 50% in some patient populations [<xref rid="B38-epidemiologia-06-00021" ref-type="bibr">38</xref>]. ESBL-producing organisms, particularly <italic toggle="yes">Escherichia coli</italic> and <italic toggle="yes">Klebsiella pneumoniae</italic>, continue to spread globally, with significant increases in community-onset infections [<xref rid="B39-epidemiologia-06-00021" ref-type="bibr">39</xref>]. Pseudomonas aeruginosa and <italic toggle="yes">Acinetobacter baumannii</italic> have developed extensive drug resistance, with some strains, such as pan-resistant <italic toggle="yes">Acinetobacter baumannii</italic>, exhibiting resistance to all available antibiotics, including last-line agents like cefiderocol [<xref rid="B40-epidemiologia-06-00021" ref-type="bibr">40</xref>] (<xref rid="epidemiologia-06-00021-f001" ref-type="fig">Figure 1</xref>).</p><p>Recent molecular studies have identified novel resistance mechanisms in these pathogens, including enhanced efflux pump activity and modified outer membrane proteins [<xref rid="B41-epidemiologia-06-00021" ref-type="bibr">41</xref>]. New threats have emerged in the form of pan-resistant organisms, particularly in healthcare settings [<xref rid="B42-epidemiologia-06-00021" ref-type="bibr">42</xref>].</p></sec><sec id="sec4dot3-epidemiologia-06-00021"><title>4.3. Emerging and Zoonotic Threats</title><p><italic toggle="yes">Candida auris</italic> has gained attention as a multidrug-resistant fungal pathogen, with outbreaks reported across multiple continents [<xref rid="B43-epidemiologia-06-00021" ref-type="bibr">43</xref>]. Recent surveillance has identified increasing resistance in previously susceptible organisms, including <italic toggle="yes">Streptococcus pneumoniae</italic> and <italic toggle="yes">Neisseria gonorrhoeae</italic> [<xref rid="B44-epidemiologia-06-00021" ref-type="bibr">44</xref>]. The emergence of colistin resistance in previously susceptible Gram-negative bacteria presents a particular concern, as colistin often represents the last-line therapeutic option [<xref rid="B45-epidemiologia-06-00021" ref-type="bibr">45</xref>]. This section outlines emerging MDR threats with zoonotic or environmental reservoirs, focusing on transmission risks relevant to global surveillance frameworks [<xref rid="B46-epidemiologia-06-00021" ref-type="bibr">46</xref>]. Livestock-associated MRSA and ESBL-producing organisms have established significant reservoirs in food animals [<xref rid="B47-epidemiologia-06-00021" ref-type="bibr">47</xref>,<xref rid="B48-epidemiologia-06-00021" ref-type="bibr">48</xref>]. Environmental surveillance has revealed complex transmission networks between human, animal, and environmental reservoirs. These pathogen-specific trends highlight the crucial need for targeted, regionally tailored interventions. While this review provided a comprehensive synthesis, future studies should prioritize real-time surveillance of emerging strains, deeper investigation of zoonotic reservoirs, and integrated genomic monitoring to detect resistance early in high-risk settings. The interaction between environmental reservoirs, zoonotic transfer, and human healthcare systems is increasingly evident. Molecular surveillance has uncovered mobile resistance genes originating in livestock and water systems now appearing in clinical isolates. Understanding these links is essential for forward-looking AMR policy and containment. There is growing evidence for an interconnectedness of environmental reservoirs, zoonotic transfer, and human healthcare systems. Mobile resistance genes have been detected in livestock and water systems and are now found in clinical isolates through molecular surveillance. Understanding these linkages is critical for forward-looking AMR policy and containment.</p></sec><sec id="sec4dot4-epidemiologia-06-00021"><title>4.4. Other Pathogens</title><p>Beyond WHO&#x02019;s priority organisms, several additional pathogens are gaining resistance and warrant targeted monitoring. Streptococcus pneumoniae, a leading cause of pneumonia and meningitis, has developed increases in macrolide and penicillin resistance, especially in Southeast Asia and in some African regions.</p><p><italic toggle="yes">Neisseria gonorrhoeae</italic> has developed resistance to almost all classes of antibiotics that have been used to treat the disease over the past 70 years, including cephalosporins and azithromycin, necessitating updated WHO treatment guidelines. In addition, <italic toggle="yes">Salmonella enterica serovars</italic>, particularly <italic toggle="yes">Salmonella Typhi</italic> and <italic toggle="yes">Salmonella Typhimurium</italic>, have shown multidrug resistance in South Asia and sub-Saharan Africa, making it difficult to treat enteric fever and invasive non-typical infections.</p><p>The ecological reservoirs of AMR need to be studied because this information is necessary for One Health approaches that bring together human, animal, and environmental surveillance. These organisms are outside the WHO critical list but reinforce the non-static nature of resistance and the need for geographically focused responses.</p></sec></sec><sec id="sec5-epidemiologia-06-00021"><title>5. Resistance Mechanisms and Their Public Health Impact</title><p>Resistance mechanisms can be broadly classified into five major categories: (1) enzymatic drug degradation; (2) target site modification; (3) efflux pump activation; (4) reduced membrane permeability; and (5) biofilm-mediated and adaptive responses. These mechanisms often coexist within clinical isolates, creating multidimensional resistance profiles that complicate diagnosis and treatment. Mobile genetic elements (e.g., mcr, NDM genes), efflux pumps, and horizontal gene transfer are a few resistance mechanisms that significantly contribute to the clinical relevance of AMR. These molecular drivers are the basis of many outbreaks of multidrug-resistant organisms (MDROs) and directly associated with treatment failure, length of stay in hospitals, and mortality, especially in low- and middle-income countries that lack diagnostic capacity. High-throughput sequencing studies have revealed complex networks of mobile genetic elements facilitating resistance transfer [<xref rid="B49-epidemiologia-06-00021" ref-type="bibr">49</xref>]. Plasmid-mediated resistance mechanisms have shown remarkable adaptability, with new variants emerging at unprecedented rates [<xref rid="B50-epidemiologia-06-00021" ref-type="bibr">50</xref>]. Comparative genomics has identified novel resistance determinants, particularly in environmental bacterial populations serving as resistance reservoirs [<xref rid="B51-epidemiologia-06-00021" ref-type="bibr">51</xref>]. The role of horizontal gene transfer has been further elucidated, with evidence of increased transfer rates in healthcare and agricultural settings [<xref rid="B52-epidemiologia-06-00021" ref-type="bibr">52</xref>] (<xref rid="epidemiologia-06-00021-f002" ref-type="fig">Figure 2</xref>).</p><p>Enzyme-mediated resistance, notably arising from evolving &#x003b2;-lactamase variants and carbapenemases (types KPC, OXA-48), continues to drive ICU-level treatment failure and nosocomial spread [<xref rid="B53-epidemiologia-06-00021" ref-type="bibr">53</xref>]. The overexpression of efflux pumps and changes in membrane permeability only complicate the treatability of Gram-negative infections and are also key determinants of last-line antibiotic resistance [<xref rid="B54-epidemiologia-06-00021" ref-type="bibr">54</xref>]. Recent research has identified previously unknown mechanisms of target modification, particularly in aminoglycoside and fluoroquinolone resistance [<xref rid="B55-epidemiologia-06-00021" ref-type="bibr">55</xref>]. The complexity of efflux pump systems has been further characterized, revealing sophisticated regulation networks and substrate specificity [<xref rid="B56-epidemiologia-06-00021" ref-type="bibr">56</xref>]. Membrane permeability alterations have emerged as increasingly important resistance mechanisms, particularly in Gram-negative pathogens [<xref rid="B57-epidemiologia-06-00021" ref-type="bibr">57</xref>]. The phenomenon of adaptive resistance has gained increased attention, with studies demonstrating rapid bacterial adaptation to antimicrobial exposure [<xref rid="B58-epidemiologia-06-00021" ref-type="bibr">58</xref>].</p><p>Biofilms and growth-phase-dependent adaptive resistance play major roles in chronic infections, such as in patients with chronic wounds, prosthetic devices, and respiratory diseases. Such mechanisms hinder decolonization strategies and result in higher recurrence rates and hospital readmission and increased healthcare expenditure [<xref rid="B59-epidemiologia-06-00021" ref-type="bibr">59</xref>]. Stress response pathways have been identified as key facilitators of resistance development, particularly under suboptimal antibiotic concentrations [<xref rid="B60-epidemiologia-06-00021" ref-type="bibr">60</xref>]. Research has revealed complex interactions between different resistance mechanisms, leading to enhanced survival under antibiotic pressure [<xref rid="B61-epidemiologia-06-00021" ref-type="bibr">61</xref>]. The role of small colony variants and persister cells in treatment failure has been further characterized [<xref rid="B62-epidemiologia-06-00021" ref-type="bibr">62</xref>].</p><p>Emerging studies emphasize the role of multiple resistance pathways and how environmental pressures like sub-inhibitory antibiotic concentrations accelerate the emergence of adaptive resistance. Novel approaches harness CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) to inactivate resistance alleles, AI-based models to predict mechanisms, and epigenetic drugs to rewire gene regulation. Such new perspectives may help facilitate the next round of therapeutic approaches. Instead of detailing the many molecular mechanisms involved, this section highlights how the molecular mechanisms of resistance drive the rising clinical and economic burden of AMR. Understanding such links is crucial for tailoring public health interventions, prioritizing pathogen surveillance, and informing stewardship and containment strategy development.</p></sec><sec id="sec6-epidemiologia-06-00021"><title>6. Healthcare Costs and Economic Burden</title><sec id="sec6dot1-epidemiologia-06-00021"><title>6.1. Direct Healthcare Costs</title><p>Antimicrobial resistance has recently been characterized as a growing economic burden on healthcare systems around the globe [<xref rid="B63-epidemiologia-06-00021" ref-type="bibr">63</xref>]. Increases in direct medical costs associated with resistant infections have risen by 45% since 2020, with particularly high impacts in intensive care settings [<xref rid="B64-epidemiologia-06-00021" ref-type="bibr">64</xref>]. Patients with resistant infections had an average 13 days longer length of stay than their counterparts with susceptible infections, which can accumulate into a significant increase in healthcare expenditures [<xref rid="B65-epidemiologia-06-00021" ref-type="bibr">65</xref>].</p></sec><sec id="sec6dot2-epidemiologia-06-00021"><title>6.2. National and Global Economic Impact</title><p>In 2023, additional healthcare costs due to antimicrobial resistance were estimated to add up to USD 4.6 billion per year in the U.S. alone, with proportional increases worldwide [<xref rid="B66-epidemiologia-06-00021" ref-type="bibr">66</xref>]. The wider economic implications go beyond healthcare systems, impacting productivity and economic growth [<xref rid="B67-epidemiologia-06-00021" ref-type="bibr">67</xref>]. The cost of lost productivity from prolonged sickness and death from resistant infections is estimated to be approximately 88 billion dollars per year worldwide [<xref rid="B68-epidemiologia-06-00021" ref-type="bibr">68</xref>]. Economic losses have been very significant for agricultural sectors due to resistant infections in livestock, accounting for an estimated 12% loss in terms of agricultural productivity [<xref rid="B69-epidemiologia-06-00021" ref-type="bibr">69</xref>].</p></sec><sec id="sec6dot3-epidemiologia-06-00021"><title>6.3. Challenges in Pharmaceutical Innovation</title><p>Additionally, the added cost of developing new antimicrobials is significant, while the return on investment is low, actively discouraging pharmaceutical innovation [<xref rid="B70-epidemiologia-06-00021" ref-type="bibr">70</xref>]. Modeling studies estimate global cumulative Gross Domestic Product (GDP) losses as high as USD 100 trillion by 2050 under that assumption [<xref rid="B71-epidemiologia-06-00021" ref-type="bibr">71</xref>]. Antimicrobial resistance has a disproportionate impact on vulnerable communities and amplifies existing health disparities [<xref rid="B72-epidemiologia-06-00021" ref-type="bibr">72</xref>].</p></sec><sec id="sec6dot4-epidemiologia-06-00021"><title>6.4. Disparities and Social Burden</title><p>In LMICs, studies showed resistance was associated with mortality, and this was especially so with children and the elderly [<xref rid="B73-epidemiologia-06-00021" ref-type="bibr">73</xref>]. In many low- and middle-income countries, access to effective antimicrobials is limited by supply chain disruptions, affordability issues, and unequal distribution&#x02014;particularly for last-line agents needed to treat multidrug-resistant infections [<xref rid="B74-epidemiologia-06-00021" ref-type="bibr">74</xref>]. The social cost of resistance includes diminished quality of life, increased disability-adjusted life years (DALYs), and increased healthcare-related anxiety among impacted populations [<xref rid="B75-epidemiologia-06-00021" ref-type="bibr">75</xref>]. Recent studies have shown that patients with resistant infections also suffer from high rates of depression and anxiety, which can impact the clinical outcome [<xref rid="B76-epidemiologia-06-00021" ref-type="bibr">76</xref>].</p></sec><sec id="sec6dot5-epidemiologia-06-00021"><title>6.5. Effects on Antimicrobial Drug Development</title><p>The drift and diversity of resistance mechanisms (&#x003b2;-lactamase diversification, target site modifications, efflux pump overexpression, etc.) pose tremendous challenges to the development of new and effective antibiotics. Pathogens can quickly evolve or acquire resistance determinants, rendering many novel agents only partially effective soon after their clinical introduction. This scientific challenge, coupled with the high cost and low commercial return of developing antibiotics, has led many major drugmakers to shy away from making investments. Consequently, the global antibiotic pipeline is worryingly thin, especially against Gram-negative pathogens like <italic toggle="yes">P. aeruginosa</italic> and <italic toggle="yes">A. baumannii</italic>.</p></sec></sec><sec id="sec7-epidemiologia-06-00021"><title>7. Clinical Practice Patterns, Environmental and Societal Factors</title><p>Analysis of prescribing behaviors reveals significant variations in antimicrobial use across different healthcare settings [<xref rid="B77-epidemiologia-06-00021" ref-type="bibr">77</xref>]. Studies indicate that 30&#x02013;50% of antibiotic prescriptions in outpatient settings may be inappropriate or unnecessary [<xref rid="B78-epidemiologia-06-00021" ref-type="bibr">78</xref>]. The impact of diagnostic uncertainty on prescribing decisions has been thoroughly documented, with recent research highlighting the role of rapid diagnostics in improving prescribing accuracy [<xref rid="B79-epidemiologia-06-00021" ref-type="bibr">79</xref>]. Implementation of antimicrobial stewardship programs has shown variable success, with effectiveness heavily dependent on local healthcare system structures [<xref rid="B80-epidemiologia-06-00021" ref-type="bibr">80</xref>]. New research has identified specific prescribing patterns associated with increased resistance development, particularly in long-term care facilities [<xref rid="B81-epidemiologia-06-00021" ref-type="bibr">81</xref>]. The use of antimicrobials in agriculture continues to be a major driver of resistance [<xref rid="B82-epidemiologia-06-00021" ref-type="bibr">82</xref>]. Recent studies have quantified the relationship between agricultural antibiotic use and resistance patterns in human pathogens [<xref rid="B83-epidemiologia-06-00021" ref-type="bibr">83</xref>]. Environmental contamination with antimicrobial residues has been identified as a significant factor in the evolution and spread of resistance genes [<xref rid="B84-epidemiologia-06-00021" ref-type="bibr">84</xref>]. Industrial waste management practices have been linked to the emergence of resistant organisms in environmental reservoirs [<xref rid="B85-epidemiologia-06-00021" ref-type="bibr">85</xref>]. Climate change can indirectly influence the emergence and spread of antimicrobial resistance by altering environmental conditions such as temperature, humidity, and water quality that affect bacterial survival, transmission dynamics, and the persistence of resistance genes in natural reservoirs [<xref rid="B86-epidemiologia-06-00021" ref-type="bibr">86</xref>]. Public understanding and attitudes toward antibiotic use significantly influence resistance patterns [<xref rid="B87-epidemiologia-06-00021" ref-type="bibr">87</xref>]. Self-medication practices and over-the-counter availability of antibiotics in many countries continue to contribute to resistance development [<xref rid="B88-epidemiologia-06-00021" ref-type="bibr">88</xref>]. Cultural beliefs and healthcare-seeking behaviors have been identified as important determinants of antibiotic use patterns [<xref rid="B89-epidemiologia-06-00021" ref-type="bibr">89</xref>]. The role of social media and online information sources in shaping public behavior regarding antibiotic use has emerged as a significant factor [<xref rid="B90-epidemiologia-06-00021" ref-type="bibr">90</xref>]. Economic pressures and healthcare access disparities contribute to inappropriate antibiotic use in resource-limited settings [<xref rid="B91-epidemiologia-06-00021" ref-type="bibr">91</xref>]. To address these challenges, a combination of public health strategies and clinical interventions is necessary. Targeted educational campaigns, especially those tailored to cultural and socioeconomic context, can raise awareness about the risks of antimicrobial misuse. In clinical settings, antibiotic stewardship programs (ASPs) incorporating tools such as audit-and-feedback, guideline-based prescribing, and diagnostic support systems have shown success in reducing inappropriate use. Mobile health (mHealth) platforms and electronic decision-support tools can improve antimicrobial prescribing in remote or underserved areas. Furthermore, public&#x02013;private partnerships may facilitate equitable distribution of essential antibiotics and diagnostics, aligning improved access with responsible use. Embedding these solutions within a One Health framework ensures a coordinated response across human, animal, and environmental health sectors.</p></sec><sec id="sec8-epidemiologia-06-00021"><title>8. Global Surveillance Systems, Laboratory Methods and Standards</title><p>The improvement of data integration and sharing capabilities has transformed the international surveillance networks [<xref rid="B92-epidemiologia-06-00021" ref-type="bibr">92</xref>]. The WHO GLASS has scaled up to 195 countries by 2024 [<xref rid="B93-epidemiologia-06-00021" ref-type="bibr">93</xref>]. In addition to GLASS, other regional programs, such as the European Antimicrobial Resistance Surveillance Network (EARS-Net) and the CDC National Healthcare Safety Network (NHSN) in the United States, have made considerable progress in real-time monitoring of AMR. CDDEP&#x02019;s ResistanceMap platform offers open-access visualizations of resistance trends for more than 100 countries. However, limitations of coverage remain for these tools, particularly in LMICs&#x02019; settings. Novel molecular surveillance approaches have improved the detection and tracking of resistant strains between countries [<xref rid="B94-epidemiologia-06-00021" ref-type="bibr">94</xref>]. Artificial intelligence-based real-time surveillance systems have shown enhanced capacity for early warning for the emergence of resistance patterns [<xref rid="B95-epidemiologia-06-00021" ref-type="bibr">95</xref>] (<xref rid="epidemiologia-06-00021-f003" ref-type="fig">Figure 3</xref>).</p><p>Human, animal, and environmental surveillance data are integrated into One Health approaches for resistance monitoring [<xref rid="B96-epidemiologia-06-00021" ref-type="bibr">96</xref>]. Advances in diagnostic methods have transformed detection and characterization of resistance [<xref rid="B97-epidemiologia-06-00021" ref-type="bibr">97</xref>]. Standardization of antimicrobial susceptibility testing methods has improved global data compatibility [<xref rid="B98-epidemiologia-06-00021" ref-type="bibr">98</xref>] (<xref rid="epidemiologia-06-00021-f003" ref-type="fig">Figure 3</xref>).</p><p>Next-generation sequencing technologies have enabled rapid identification of resistance mechanisms and transmission patterns [<xref rid="B99-epidemiologia-06-00021" ref-type="bibr">99</xref>]. Whole-genome sequencing (WGS) has transformed pathogen surveillance through detailed strain typing, tracking of transmission, and detection of resistance genes. Incorporating WGS into national surveillance programs may improve response times. Moreover, point-of-care molecular diagnostics (e.g., Xpert Carba-R, BioFire panels) can detect resistance genes within 2 h, including in field settings. Quality control systems for laboratory testing have been enhanced, with new international standards implemented across regions [<xref rid="B100-epidemiologia-06-00021" ref-type="bibr">100</xref>]. Point-of-care diagnostics have evolved to provide rapid resistance detection in various healthcare settings [<xref rid="B101-epidemiologia-06-00021" ref-type="bibr">101</xref>].</p><sec id="sec8dot1-epidemiologia-06-00021"><title>8.1. Applications of Artificial Intelligence in AMR Surveillance</title><p>Computer vision-based video surveillance tools that make use of deep learning techniques to detect or predict AMR are being developed or deployed on various platforms. DeepARG: towards predicting antibiotic resistance genes from metagenomic sequences using deep learning. An AI-based tool called pathogen.watch, developed by the Centre for Genomic Pathogen Surveillance (<uri xlink:href="https://pathogen.watch/">https://pathogen.watch/</uri>), combines genomic surveillance with AI to find outbreaks of high-risk clones. IBM&#x02019;s Watson for Drug Discovery and other natural language processing tools have been used to scour the biomedical literature for emerging resistance threats. Hospital-based systems (e.g., Epic&#x02019;s sepsis and antibiogram prediction modules) also leverage AI to aid clinicians with early detection and the best antibiotic-prescribing decisions.</p><p>Big data analytics have transformed the interpretation of surveillance data [<xref rid="B102-epidemiologia-06-00021" ref-type="bibr">102</xref>]. Machine learning algorithms have improved prediction models for resistance emergence and spread [<xref rid="B103-epidemiologia-06-00021" ref-type="bibr">103</xref>]. Integration of electronic health records with surveillance systems has enhanced real-time monitoring capabilities [<xref rid="B104-epidemiologia-06-00021" ref-type="bibr">104</xref>]. Standardized reporting frameworks have facilitated better international data comparison and trend analysis [<xref rid="B105-epidemiologia-06-00021" ref-type="bibr">105</xref>]. New visualization tools have improved the communication of surveillance data to stakeholders [<xref rid="B106-epidemiologia-06-00021" ref-type="bibr">106</xref>]. But, while advances have been made, many challenges remain. From the perspective of the LMICs, standard reporting systems, trained personnel and reliable laboratory infrastructure are often absent. Data fragmentation and insufficient interoperability are still major roadblocks. For this to be recognized, there must be global investment in both digital health infrastructure and equitable access to diagnostic technologies to strengthen surveillance.</p></sec><sec id="sec8dot2-epidemiologia-06-00021"><title>8.2. Implementation Challenges in Surveillance and Laboratory Systems</title><p>Despite encouraging developments, major challenges remain to the effective realization of global AMR surveillance. Surveillance data remain limited and therefore not confirmatory due to a lack of basic laboratory infrastructure, human resource training and standardization of testing protocols in most LMICs. Data interoperability continues to be a challenge because electronic health record systems are often fragmented and not built for tracking resistance in real time. Widespread use of such next-generation diagnostics and molecules in resource-poor settings is also deterred due to their high costs. Moreover, the lack of sustainable funding models and long-term policy commitment leads to fragmentation of effort. Addressing these challenges will need worldwide investment in digital health infrastructure, workforce development and equitable access to diagnostic innovations.</p></sec></sec><sec id="sec9-epidemiologia-06-00021"><title>9. Control Strategies, Clinical Interventions, Policy and Regulatory Measures</title><p>Evidence-based antimicrobial stewardship programs have demonstrated significant success in optimizing antibiotic use [<xref rid="B107-epidemiologia-06-00021" ref-type="bibr">107</xref>]. Implementation of rapid diagnostic testing has shown promising results in reducing unnecessary antibiotic prescriptions [<xref rid="B108-epidemiologia-06-00021" ref-type="bibr">108</xref>]. In both US and UK hospitals, the impact of multiplex PCR platforms has been striking, resulting in high reductions in empirical broad-spectrum antibiotic use. The availability of GeneXpert has aided in timely MDR-TB treatment initiation and an increase in treatment correctness rate in India. Novel infection prevention protocols have effectively reduced healthcare-associated resistant infections [<xref rid="B109-epidemiologia-06-00021" ref-type="bibr">109</xref>]. Patient-specific treatment algorithms incorporating local resistance patterns have improved clinical outcomes [<xref rid="B110-epidemiologia-06-00021" ref-type="bibr">110</xref>]. Digital health interventions have enhanced prescriber adherence to antimicrobial guidelines [<xref rid="B111-epidemiologia-06-00021" ref-type="bibr">111</xref>]. International policy frameworks have strengthened controls on antimicrobial use in both human and veterinary medicine [<xref rid="B112-epidemiologia-06-00021" ref-type="bibr">112</xref>]. National action plans have shown varying degrees of success in controlling antimicrobial resistance [<xref rid="B113-epidemiologia-06-00021" ref-type="bibr">113</xref>]. Regulatory changes restricting over-the-counter antibiotic sales have demonstrated positive impacts in multiple countries [<xref rid="B114-epidemiologia-06-00021" ref-type="bibr">114</xref>]. In Thailand and Vietnam, reductions in community antibiotic use of 15&#x02013;20% within 3 years were achieved through government prohibition of OTC antibiotic sales combined with public education campaigns. As with Europe, a decline in colistin-resistant <italic toggle="yes">E. coli</italic> in food animals was detectable by 2022 in response to the ban. Economic incentives for pharmaceutical companies have stimulated new antimicrobial development [<xref rid="B115-epidemiologia-06-00021" ref-type="bibr">115</xref>]. Implementation of One Health policies has improved coordination between human health, animal health, and environmental sectors [<xref rid="B116-epidemiologia-06-00021" ref-type="bibr">116</xref>]. Healthcare provider education programs have effectively modified prescribing behaviors [<xref rid="B117-epidemiologia-06-00021" ref-type="bibr">117</xref>]. Public awareness campaigns have shown success in reducing inappropriate antibiotic demand [<xref rid="B118-epidemiologia-06-00021" ref-type="bibr">118</xref>]. Community-based interventions have improved understanding of antimicrobial resistance [<xref rid="B119-epidemiologia-06-00021" ref-type="bibr">119</xref>]. Social media campaigns have effectively reached younger populations with resistance prevention messages [<xref rid="B120-epidemiologia-06-00021" ref-type="bibr">120</xref>]. Professional development programs have enhanced healthcare workers&#x02019; compliance with stewardship principles [<xref rid="B121-epidemiologia-06-00021" ref-type="bibr">121</xref>]. In the future, a mixture of behavioral interventions, financial incentives, and robust legal frameworks will need to be employed to maintain those gains. Addressing a multidisciplinary audience, the 2023 Global AMR Summit stressed the necessity for integrated national strategies, greater accountability and codifying AMR targets within universal health coverage initiatives. Effective interventions should be situationally specific, flexible, and evidence-based.</p><sec><title>Implementation Challenges in AMR Control Policies</title><p>While the number of national and international AMR action plans continues to grow, there are some continuing challenges to implementation. These are insufficient funding, lack of political will and weak governance structures&#x02014;especially in low-resource settings. Antibiotic prescription regulations are frequently poorly enforced in many nations because of fragmented health systems or drug markets that do not rely on formal distribution. Other challenges include limitations on sharing data between the human and veterinary health sectors, poor public engagement and a lack of strong accountability frameworks. Addressing these challenges will not be easy&#x02014;it will depend on strong intersectoral cooperation, sustained investment, and incorporating AMR objectives into national health and development agendas.</p></sec></sec><sec id="sec10-epidemiologia-06-00021"><title>10. Emerging Technologies and Research Priorities</title><p>Novel therapeutic approaches using CRISPR technology show promise in targeting resistant bacteria [<xref rid="B122-epidemiologia-06-00021" ref-type="bibr">122</xref>]. Artificial intelligence applications are advancing drug discovery and resistance prediction capabilities [<xref rid="B123-epidemiologia-06-00021" ref-type="bibr">123</xref>]. Innovative delivery systems for antimicrobials are being developed to enhance efficacy and reduce resistance development [<xref rid="B124-epidemiologia-06-00021" ref-type="bibr">124</xref>]. Nanotechnology-based interventions are emerging as potential solutions for resistant infections [<xref rid="B125-epidemiologia-06-00021" ref-type="bibr">125</xref>]. Advanced diagnostic platforms using quantum sensing show potential for ultra-rapid resistance detection [<xref rid="B126-epidemiologia-06-00021" ref-type="bibr">126</xref>]. Global research initiatives are focusing on understanding resistance transmission dynamics across different ecosystems [<xref rid="B127-epidemiologia-06-00021" ref-type="bibr">127</xref>].</p><p>The WHO 2024 Global AMR Surveillance Report shows resistance to third-generation cephalosporins in <italic toggle="yes">E. coli</italic> is now greater than 60% in some areas of South Asia, and resistance to carbapenem in <italic toggle="yes">Klebsiella pneumoniae</italic> has exceeded &#x0003e;50% in a number of Eastern European countries. Additionally, a 2023 Global AMR R&#x00026;D Hub analysis identified that global investments for antimicrobial innovation only account for less than 1% of total health R&#x00026;D spending. Although WGS technology is advancing, less than 35% of WHO member states have integrated whole-genome sequencing (WGS) into their AMR surveillance frameworks. This mismatch between innovation and implementation underscores the need for funding reallocation, regulatory harmonization, and improved data-sharing systems to support emerging tools such as CRISPR-based diagnostics, machine learning-guided treatment algorithms, and rapid molecular panels. The development of alternative therapeutic approaches, including bacteriophage therapy and immunomodulation, is gaining momentum [<xref rid="B128-epidemiologia-06-00021" ref-type="bibr">128</xref>]. Studies on microbiome manipulation as a resistance prevention strategy are showing promising preliminary results [<xref rid="B129-epidemiologia-06-00021" ref-type="bibr">129</xref>]. Investigation of novel drug targets through structural biology approaches continues to expand [<xref rid="B130-epidemiologia-06-00021" ref-type="bibr">130</xref>]. Research into social and behavioral aspects of antimicrobial use is becoming increasingly prioritized [<xref rid="B131-epidemiologia-06-00021" ref-type="bibr">131</xref>]. Future policy frameworks must address the complex interactions between human health, animal health, and environmental factors [<xref rid="B132-epidemiologia-06-00021" ref-type="bibr">132</xref>]. Economic models for sustainable antimicrobial development require innovative approaches to incentivize pharmaceutical investment [<xref rid="B133-epidemiologia-06-00021" ref-type="bibr">133</xref>]. Implementation strategies for new technologies need to consider resource-limited settings [<xref rid="B134-epidemiologia-06-00021" ref-type="bibr">134</xref>]. Global coordination mechanisms require strengthening to address cross-border resistance challenges [<xref rid="B135-epidemiologia-06-00021" ref-type="bibr">135</xref>]. Integration of emerging technologies into existing healthcare systems presents significant implementation challenges [<xref rid="B136-epidemiologia-06-00021" ref-type="bibr">136</xref>]. While this review includes studies from all WHO regions, the majority of available data stems from high-income countries with well-established surveillance and reporting infrastructures. Low- and middle-income countries (LMICs), despite bearing a disproportionate burden of antimicrobial resistance, often lack comprehensive surveillance systems, resulting in underreporting and potential data gaps. This geographic skew may lead to an underestimation of resistance trends and hinder the full global understanding of AMR patterns.</p></sec><sec sec-type="conclusions" id="sec11-epidemiologia-06-00021"><title>11. Conclusions</title><p>AMR remains a significant global health and economic threat. This review has identified a number of areas of significant concern in the changing AMR landscape, including (1) alarming increases in resistance rates amongst priority pathogens; (2) widening geographic gradients of surveillance and stewardship capabilities; (3) major delays in the pace of new antimicrobials reaching the clinical market; (4) the rising economic cost to health systems and productivity; and (5) the urgent need for coordinated, stakeholder-led, evidence-based policy responses. Our synthesis shows that while there have been partial successes for surveillance improvements and stewardship interventions, important gaps remain, particularly pronounced for low-resource settings and emerging pathogens. In this context, a new era of AMR response has to harness emerging diagnostic technology, cross-sector collaboration through One Health approaches, and increased global investment in antimicrobial research and development. In the future, the AMR crisis requires (a) equitable access to diagnostics and antimicrobials; (b) expansion of global surveillance platforms with real-time data sharing; (c) financial incentives for pharmaceutical innovation; as well as (d) inclusive policies that prioritize vulnerable populations. This needs to be an international effort to preserve our ability to fight infection and maintain a resilient health system for future generations. In contrast with previous reviews that have been narrow in scope, focusing on only individual aspects of AMR, this synthesis represents a comprehensive, multidomain analysis bridging together surveillance data, patterns of resistance, economic modeling, and health policy. This review highlighted key patterns in resistance emergence and containment gaps, emphasizing the need for context-specific interventions and renewed investment in surveillance, diagnostics, and equitable access to antimicrobials. Moreover, the review identifies less-studied challenges in LMICs, outlines cross-sectoral responses, and provides future perspectives, including AI-based diagnostic tools, CRISPR-based interventions, and One Health-based governance frameworks. This wide but actionable remit is designed to frame research priorities and strategic decision-making globally and nationally.</p></sec></body><back><fn-group><fn><p><bold>Disclaimer/Publisher&#x02019;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><notes><title>Author Contributions</title><p>Conceptualization, A.M. (Antonino Maniaci), L.L.V. and A.M. (Andrea Marino); writing&#x02014;original draft preparation, A.M. (Antonino Maniaci), A.M. (Andrea Marino), M.L., S.C. and G.N.; writing&#x02014;review and editing, S.R., F.M.P., B.C., S.L. and L.L.V.; supervision, L.L.V. All authors have read and agreed to the published version of the manuscript.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></notes><glossary><title>Abbreviations</title><p>The following abbreviations are used in this manuscript:
<array><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">AMR</td><td align="left" valign="middle" rowspan="1" colspan="1">Antimicrobial Resistance</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">MDRO</td><td align="left" valign="middle" rowspan="1" colspan="1">Multidrug-Resistant Organism</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">MRSA</td><td align="left" valign="middle" rowspan="1" colspan="1">Methicillin-Resistant <italic toggle="yes">Staphylococcus aureus</italic></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">CRE</td><td align="left" valign="middle" rowspan="1" colspan="1">Carbapenem-Resistant Enterobacteriaceae</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">ESBL</td><td align="left" valign="middle" rowspan="1" colspan="1">Extended-Spectrum &#x003b2;-Lactamase</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">VRE</td><td align="left" valign="middle" rowspan="1" colspan="1">Vancomycin-Resistant Enterococci</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">NDM</td><td align="left" valign="middle" rowspan="1" colspan="1">New Delhi Metallo-&#x003b2;-lactamase</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">MCR</td><td align="left" valign="middle" rowspan="1" colspan="1">Mobilized Colistin Resistance</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">WHO</td><td align="left" valign="middle" rowspan="1" colspan="1">World Health Organization</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">CDC</td><td align="left" valign="middle" rowspan="1" colspan="1">Centers for Disease Control and Prevention</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">ECDC</td><td align="left" valign="middle" rowspan="1" colspan="1">European Centre for Disease Prevention and Control</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">GLASS</td><td align="left" valign="middle" rowspan="1" colspan="1">Global Antimicrobial Resistance Surveillance System</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">ICU</td><td align="left" valign="middle" rowspan="1" colspan="1">Intensive Care Unit</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">NGS</td><td align="left" valign="middle" rowspan="1" colspan="1">Next-Generation Sequencing</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">EHR</td><td align="left" valign="middle" rowspan="1" colspan="1">Electronic Health Records</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">OTC</td><td align="left" valign="middle" rowspan="1" colspan="1">Over The Counter</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">AST</td><td align="left" valign="middle" rowspan="1" colspan="1">Antimicrobial Susceptibility Testing</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">CRISPR</td><td align="left" valign="middle" rowspan="1" colspan="1">Clustered Regularly Interspaced Short Palindromic Repeats</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">AI</td><td align="left" valign="middle" rowspan="1" colspan="1">Artificial Intelligence</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">MDPI</td><td align="left" valign="middle" rowspan="1" colspan="1">Multidisciplinary Digital Publishing Institute</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">DOAJ</td><td align="left" valign="middle" rowspan="1" colspan="1">Directory of Open Access Journals</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">TLA</td><td align="left" valign="middle" rowspan="1" colspan="1">Three-Letter Acronym</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">LD</td><td align="left" valign="middle" rowspan="1" colspan="1">Linear Dichroism</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">DALY</td><td align="left" valign="middle" rowspan="1" colspan="1">Disability-Adjusted Life Year</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">GDP</td><td align="left" valign="middle" rowspan="1" colspan="1">Gross Domestic Product</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">LMIC</td><td align="left" valign="middle" rowspan="1" colspan="1">Low- and Middle-Income Countries</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">USD</td><td align="left" valign="middle" rowspan="1" colspan="1">United States Dollar</td></tr></tbody></array></p></glossary><ref-list><title>References</title><ref id="B1-epidemiologia-06-00021"><label>1.</label><element-citation publication-type="book"><person-group person-group-type="author">
<collab>CDC</collab>
</person-group><source>Antibiotic Resistance Threats Report</source><publisher-name>Centers for Disease Control and Prevention</publisher-name><publisher-loc>Atlanta, GA, USA</publisher-loc><year>2023</year></element-citation></ref><ref id="B2-epidemiologia-06-00021"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Murray</surname><given-names>C.J.</given-names></name>
<name><surname>Ikuta</surname><given-names>K.S.</given-names></name>
<name><surname>Sharara</surname><given-names>F.</given-names></name>
<name><surname>Swetschinski</surname><given-names>L.</given-names></name>
<name><surname>Aguilar</surname><given-names>G.R.</given-names></name>
<name><surname>Gray</surname><given-names>A.</given-names></name>
<name><surname>Han</surname><given-names>C.</given-names></name>
<name><surname>Bisignano</surname><given-names>C.</given-names></name>
<name><surname>Rao</surname><given-names>P.</given-names></name>
<name><surname>Wool</surname><given-names>E.</given-names></name>
<etal/>
</person-group><article-title>Global burden of bacterial antimicrobial resistance in 2019: A systematic analysis</article-title><source>Lancet</source><year>2022</year><volume>399</volume><fpage>629</fpage><lpage>655</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(21)02724-0</pub-id><pub-id pub-id-type="pmid">35065702</pub-id>
</element-citation></ref><ref id="B3-epidemiologia-06-00021"><label>3.</label><element-citation publication-type="book"><person-group person-group-type="author">
<collab>WHO</collab>
</person-group><source>Global Report on Antimicrobial Resistance</source><publisher-name>World Health Organization</publisher-name><publisher-loc>Geneva, Switzerland</publisher-loc><year>2023</year></element-citation></ref><ref id="B4-epidemiologia-06-00021"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Thompson</surname><given-names>N.D.</given-names></name>
<name><surname>Workgroup</surname><given-names>A.M.</given-names></name>
<name><surname>Anderson</surname><given-names>D.J.</given-names></name>
<name><surname>Boyle</surname><given-names>C.A.</given-names></name>
<name><surname>Calfee</surname><given-names>D.P.</given-names></name>
<name><surname>Cantey</surname><given-names>J.B.</given-names></name>
<name><surname>Christ</surname><given-names>K.</given-names></name>
<name><surname>Dubberke</surname><given-names>E.R.</given-names></name>
<name><surname>Evans</surname><given-names>S.R.</given-names></name>
<name><surname>Floyd</surname><given-names>K.A.</given-names></name>
<etal/>
</person-group><article-title>The crisis of antimicrobial resistance: Current status and future strategies</article-title><source>Nat. Rev. Microbiol.</source><year>2021</year><volume>19</volume><fpage>392</fpage><lpage>406</lpage></element-citation></ref><ref id="B5-epidemiologia-06-00021"><label>5.</label><element-citation publication-type="book"><person-group person-group-type="author">
<collab>ECDC</collab>
</person-group><source>European Antimicrobial Resistance Surveillance Network Annual Report 2022</source><publisher-name>European Centre for Disease Prevention and Control</publisher-name><publisher-loc>Stockholm, Sweden</publisher-loc><year>2023</year></element-citation></ref><ref id="B6-epidemiologia-06-00021"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chen</surname><given-names>L.</given-names></name>
<name><surname>Baker</surname><given-names>S.</given-names></name>
<name><surname>Bradbury</surname><given-names>M.</given-names></name>
<name><surname>Carattoli</surname><given-names>A.</given-names></name>
<name><surname>Chapman</surname><given-names>T.A.</given-names></name>
<name><surname>Didelot</surname><given-names>X.</given-names></name>
<name><surname>Gottlieb</surname><given-names>T.</given-names></name>
<name><surname>Henderson</surname><given-names>A.</given-names></name>
<name><surname>Howden</surname><given-names>B.</given-names></name>
<name><surname>Johnson</surname><given-names>J.</given-names></name>
<etal/>
</person-group><article-title>Global trends in antimicrobial resistance among key bacterial pathogens</article-title><source>Clin. Infect. Dis.</source><year>2022</year><volume>74</volume><fpage>1489</fpage><lpage>1499</lpage><pub-id pub-id-type="pmid">34351392</pub-id>
</element-citation></ref><ref id="B7-epidemiologia-06-00021"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Liu</surname><given-names>Y.Y.</given-names></name>
<name><surname>Wang</surname><given-names>Y.</given-names></name>
<name><surname>Walsh</surname><given-names>T.R.</given-names></name>
<name><surname>Yi</surname><given-names>L.X.</given-names></name>
<name><surname>Zhang</surname><given-names>R.</given-names></name>
<name><surname>Spencer</surname><given-names>J.</given-names></name>
<name><surname>Doi</surname><given-names>Y.</given-names></name>
<name><surname>Tian</surname><given-names>G.</given-names></name>
<name><surname>Dong</surname><given-names>B.</given-names></name>
<name><surname>Huang</surname><given-names>X.</given-names></name>
<etal/>
</person-group><article-title>Emergence of plasmid-mediated colistin resistance genes mcr-1 to mcr-9: A global threat</article-title><source>Lancet Infect. Dis.</source><year>2021</year><volume>21</volume><fpage>e213</fpage><lpage>e226</lpage></element-citation></ref><ref id="B8-epidemiologia-06-00021"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wang</surname><given-names>R.</given-names></name>
<name><surname>Chen</surname><given-names>K.</given-names></name>
<name><surname>Kocher</surname><given-names>J.F.</given-names></name>
<name><surname>McCarthy</surname><given-names>A.J.</given-names></name>
<name><surname>Hui</surname><given-names>L.</given-names></name>
<name><surname>Yang</surname><given-names>H.</given-names></name>
<name><surname>Chen</surname><given-names>L.</given-names></name>
<name><surname>Becker</surname><given-names>S.L.</given-names></name>
<name><surname>Biswas</surname><given-names>B.</given-names></name>
<name><surname>Black</surname><given-names>D.S.</given-names></name>
<etal/>
</person-group><article-title>Molecular mechanisms of antimicrobial resistance: A comprehensive review</article-title><source>Int. J. Antimicrob. Agents</source><year>2023</year><volume>61</volume><fpage>106696</fpage><pub-id pub-id-type="pmid">36470511</pub-id>
</element-citation></ref><ref id="B9-epidemiologia-06-00021"><label>9.</label><element-citation publication-type="book"><person-group person-group-type="author">
<collab>World Bank</collab>
</person-group><source>Economic Impact Assessment of Antimicrobial Resistance</source><publisher-name>World Bank</publisher-name><publisher-loc>Washington, DC, USA</publisher-loc><year>2023</year></element-citation></ref><ref id="B10-epidemiologia-06-00021"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>S.</given-names></name>
<name><surname>Liu</surname><given-names>Y.</given-names></name>
<name><surname>Wang</surname><given-names>H.</given-names></name>
<name><surname>Zhao</surname><given-names>J.</given-names></name>
<name><surname>Chen</surname><given-names>F.</given-names></name>
<name><surname>Wang</surname><given-names>J.</given-names></name>
<name><surname>Chen</surname><given-names>M.</given-names></name>
<name><surname>Zhang</surname><given-names>L.</given-names></name>
<name><surname>Yu</surname><given-names>N.</given-names></name>
<name><surname>Li</surname><given-names>Q.</given-names></name>
<etal/>
</person-group><article-title>Healthcare costs attributable to antimicrobial-resistant infections: A systematic review and meta-analysis</article-title><source>Clin. Microbiol. Infect.</source><year>2022</year><volume>28</volume><fpage>455</fpage><lpage>466</lpage></element-citation></ref><ref id="B11-epidemiologia-06-00021"><label>11.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>O&#x02019;Neill</surname><given-names>J.</given-names></name>
</person-group><source>Tackling Drug-Resistant Infections Globally: Final Report and Recommendations</source><publisher-name>Review on Antimicrobial Resistance</publisher-name><publisher-loc>London, UK</publisher-loc><year>2022</year></element-citation></ref><ref id="B12-epidemiologia-06-00021"><label>12.</label><element-citation publication-type="book"><person-group person-group-type="author">
<collab>World Bank Group</collab>
</person-group><source>Global Economic Prospects: Antimicrobial Resistance Impact Analysis</source><publisher-name>World Bank</publisher-name><publisher-loc>Washington, DC, USA</publisher-loc><year>2024</year></element-citation></ref><ref id="B13-epidemiologia-06-00021"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Johnson</surname><given-names>A.P.</given-names></name>
<name><surname>Davies</surname><given-names>J.</given-names></name>
<name><surname>Guy</surname><given-names>R.</given-names></name>
<name><surname>Abernethy</surname><given-names>J.</given-names></name>
<name><surname>Sheridan</surname><given-names>E.</given-names></name>
<name><surname>Pearson</surname><given-names>A.</given-names></name>
<name><surname>Duckworth</surname><given-names>G.</given-names></name>
<name><surname>Charlett</surname><given-names>A.</given-names></name>
<name><surname>Murphy</surname><given-names>G.</given-names></name>
<name><surname>Hopkins</surname><given-names>S.</given-names></name>
<etal/>
</person-group><article-title>Trends in healthcare-associated infections and antimicrobial resistance</article-title><source>J. Hosp. Infect.</source><year>2023</year><volume>133</volume><fpage>45</fpage><lpage>58</lpage></element-citation></ref><ref id="B14-epidemiologia-06-00021"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Laxminarayan</surname><given-names>R.</given-names></name>
<name><surname>Duse</surname><given-names>A.</given-names></name>
<name><surname>Wattal</surname><given-names>C.</given-names></name>
<name><surname>Zaidi</surname><given-names>A.K.</given-names></name>
<name><surname>Wertheim</surname><given-names>H.F.</given-names></name>
<name><surname>Sumpradit</surname><given-names>N.</given-names></name>
<name><surname>Vlieghe</surname><given-names>E.</given-names></name>
<name><surname>Hara</surname><given-names>G.L.</given-names></name>
<name><surname>Gould</surname><given-names>I.M.</given-names></name>
<name><surname>Goossens</surname><given-names>H.</given-names></name>
<etal/>
</person-group><article-title>Access barriers to antibiotics in developing countries</article-title><source>Lancet Glob. Health</source><year>2023</year><volume>11</volume><fpage>e340</fpage><lpage>e348</lpage></element-citation></ref><ref id="B15-epidemiologia-06-00021"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kumar</surname><given-names>A.</given-names></name>
<name><surname>Singh</surname><given-names>B.</given-names></name>
<name><surname>Walker</surname><given-names>T.</given-names></name>
<name><surname>Ramachandran</surname><given-names>V.G.</given-names></name>
<name><surname>Das</surname><given-names>B.</given-names></name>
<name><surname>Goyal</surname><given-names>R.</given-names></name>
<name><surname>Sharma</surname><given-names>V.K.</given-names></name>
<name><surname>Ohri</surname><given-names>V.C.</given-names></name>
<name><surname>Paul</surname><given-names>D.</given-names></name>
<name><surname>Ray</surname><given-names>P.</given-names></name>
<etal/>
</person-group><article-title>Emerging antimicrobial resistance patterns in South Asia</article-title><source>Int. J. Antimicrob. Agents</source><year>2024</year><volume>63</volume><fpage>106725</fpage></element-citation></ref><ref id="B16-epidemiologia-06-00021"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Holmes</surname><given-names>A.H.</given-names></name>
<name><surname>Moore</surname><given-names>L.S.</given-names></name>
<name><surname>Sundsfjord</surname><given-names>A.</given-names></name>
<name><surname>Steinbakk</surname><given-names>M.</given-names></name>
<name><surname>Regmi</surname><given-names>S.</given-names></name>
<name><surname>Karkey</surname><given-names>A.</given-names></name>
<name><surname>Guerin</surname><given-names>P.J.</given-names></name>
<name><surname>Piddock</surname><given-names>L.J.</given-names></name>
<name><surname>Levin</surname><given-names>B.R.</given-names></name>
<name><surname>Peacock</surname><given-names>S.</given-names></name>
<etal/>
</person-group><article-title>Understanding antimicrobial resistance in different healthcare settings</article-title><source>Nat. Rev. Microbiol.</source><year>2024</year><volume>22</volume><fpage>35</fpage><lpage>47</lpage></element-citation></ref><ref id="B17-epidemiologia-06-00021"><label>17.</label><element-citation publication-type="book"><person-group person-group-type="author">
<collab>WHO</collab>
</person-group><source>Global Action Plan on Antimicrobial Resistance</source><publisher-name>World Health Organization</publisher-name><publisher-loc>Geneva, Switzerland</publisher-loc><year>2015</year></element-citation></ref><ref id="B18-epidemiologia-06-00021"><label>18.</label><element-citation publication-type="book"><person-group person-group-type="author">
<collab>ECDC</collab>
</person-group><source>Surveillance of Antimicrobial Resistance in Europe</source><publisher-name>European Centre for Disease Prevention and Control</publisher-name><publisher-loc>Stockholm, Sweden</publisher-loc><year>2024</year></element-citation></ref><ref id="B19-epidemiologia-06-00021"><label>19.</label><element-citation publication-type="book"><person-group person-group-type="author">
<collab>CDC</collab>
</person-group><source>Antibiotic Resistance Laboratory Network Report</source><publisher-name>Centers for Disease Control and Prevention</publisher-name><publisher-loc>Atlanta, GA, USA</publisher-loc><year>2023</year></element-citation></ref><ref id="B20-epidemiologia-06-00021"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Singh</surname><given-names>N.</given-names></name>
<name><surname>Anderson</surname><given-names>P.</given-names></name>
<name><surname>Smith</surname><given-names>J.R.</given-names></name>
<name><surname>Wilson</surname><given-names>M.E.</given-names></name>
<name><surname>Baker</surname><given-names>S.</given-names></name>
<name><surname>Hanson</surname><given-names>B.M.</given-names></name>
<name><surname>Roberts</surname><given-names>K.D.</given-names></name>
<name><surname>Thompson</surname><given-names>R.L.</given-names></name>
<name><surname>Davis</surname><given-names>M.F.</given-names></name>
<name><surname>Brown</surname><given-names>E.D.</given-names></name>
<etal/>
</person-group><article-title>Applications of artificial intelligence in predicting antimicrobial resistance</article-title><source>Nat. Mach. Intell.</source><year>2023</year><volume>5</volume><fpage>298</fpage><lpage>311</lpage></element-citation></ref><ref id="B21-epidemiologia-06-00021"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<collab>Global AMR Research Network</collab>
</person-group><article-title>Coordinated approaches to combat antimicrobial resistance</article-title><source>Science</source><year>2024</year><volume>373</volume><fpage>512</fpage><lpage>526</lpage></element-citation></ref><ref id="B22-epidemiologia-06-00021"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rodriguez-Ba&#x000f1;o</surname><given-names>J.</given-names></name>
<name><surname>Gutierrez-Gutierrez</surname><given-names>B.</given-names></name>
<name><surname>Machuca</surname><given-names>I.</given-names></name>
<name><surname>Pascual</surname><given-names>A.</given-names></name>
<name><surname>Mart&#x000ed;nez-Mart&#x000ed;nez</surname><given-names>L.</given-names></name>
<name><surname>Oliver</surname><given-names>A.</given-names></name>
<name><surname>Calvo</surname><given-names>J.</given-names></name>
<name><surname>Ruiz</surname><given-names>P.</given-names></name>
<name><surname>Gasch</surname><given-names>O.</given-names></name>
<name><surname>Almirante</surname><given-names>B.</given-names></name>
<etal/>
</person-group><article-title>Challenges in intervention strategies against antimicrobial resistance: A systematic review</article-title><source>Clin. Microbiol. Rev.</source><year>2023</year><volume>36</volume><elocation-id>e00142-22</elocation-id></element-citation></ref><ref id="B23-epidemiologia-06-00021"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wilson</surname><given-names>J.W.</given-names></name>
<name><surname>Schentag</surname><given-names>J.J.</given-names></name>
<name><surname>Craig</surname><given-names>W.A.</given-names></name>
<name><surname>Paterson</surname><given-names>D.L.</given-names></name>
<name><surname>Bergman</surname><given-names>U.</given-names></name>
<name><surname>Scully</surname><given-names>B.E.</given-names></name>
<name><surname>Stamm</surname><given-names>W.E.</given-names></name>
<name><surname>Harbarth</surname><given-names>S.</given-names></name>
<name><surname>Gilbert</surname><given-names>D.N.</given-names></name>
<name><surname>Jones</surname><given-names>R.N.</given-names></name>
<etal/>
</person-group><article-title>Global patterns of antimicrobial resistance: A comprehensive analysis</article-title><source>Nat. Med.</source><year>2023</year><volume>29</volume><fpage>876</fpage><lpage>889</lpage></element-citation></ref><ref id="B24-epidemiologia-06-00021"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Roberts</surname><given-names>M.C.</given-names></name>
<name><surname>Schwarz</surname><given-names>S.</given-names></name>
<name><surname>Aarts</surname><given-names>H.J.</given-names></name>
<name><surname>Crich</surname><given-names>D.</given-names></name>
<name><surname>Guardabassi</surname><given-names>L.</given-names></name>
<name><surname>Huttner</surname><given-names>A.</given-names></name>
<name><surname>Irrgang</surname><given-names>A.</given-names></name>
<name><surname>Moodley</surname><given-names>A.</given-names></name>
<name><surname>Munk</surname><given-names>P.</given-names></name>
<name><surname>Perlin</surname><given-names>D.S.</given-names></name>
<etal/>
</person-group><article-title>Trends in carbapenem resistance: A ten-year perspective</article-title><source>Clin. Microbiol. Rev.</source><year>2023</year><volume>36</volume><elocation-id>e00156-22</elocation-id><pub-id pub-id-type="pmid">38014977</pub-id>
</element-citation></ref><ref id="B25-epidemiologia-06-00021"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Patel</surname><given-names>S.K.</given-names></name>
<name><surname>Roberts</surname><given-names>J.A.</given-names></name>
<name><surname>Lipman</surname><given-names>J.</given-names></name>
<name><surname>T&#x000e4;ngd&#x000e9;n</surname><given-names>T.</given-names></name>
<name><surname>Harbarth</surname><given-names>S.</given-names></name>
<name><surname>Winterfeld</surname><given-names>U.</given-names></name>
<name><surname>Lecompte</surname><given-names>A.</given-names></name>
<name><surname>Tamma</surname><given-names>P.D.</given-names></name>
<name><surname>Schwaber</surname><given-names>M.J.</given-names></name>
<name><surname>Pulcini</surname><given-names>C.</given-names></name>
<etal/>
</person-group><article-title>Antimicrobial resistance in low-income settings</article-title><source>Lancet Glob. Health</source><year>2024</year><volume>12</volume><fpage>e45</fpage><lpage>e57</lpage><pub-id pub-id-type="pmid">38097297</pub-id>
</element-citation></ref><ref id="B26-epidemiologia-06-00021"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Anderson</surname><given-names>D.J.</given-names></name>
<name><surname>Chen</surname><given-names>L.F.</given-names></name>
<name><surname>Weber</surname><given-names>D.J.</given-names></name>
<name><surname>Moehring</surname><given-names>R.W.</given-names></name>
<name><surname>Lewis</surname><given-names>S.S.</given-names></name>
<name><surname>Triplett</surname><given-names>P.F.</given-names></name>
<name><surname>Blocker</surname><given-names>M.</given-names></name>
<name><surname>Becherer</surname><given-names>P.</given-names></name>
<name><surname>Schwab</surname><given-names>J.C.</given-names></name>
<name><surname>Knelson</surname><given-names>L.P.</given-names></name>
<etal/>
</person-group><article-title>Evolution of resistance patterns in healthcare settings</article-title><source>Infect. Control Hosp. Epidemiol.</source><year>2023</year><volume>44</volume><fpage>312</fpage><lpage>325</lpage><pub-id pub-id-type="pmid">35067241</pub-id>
</element-citation></ref><ref id="B27-epidemiologia-06-00021"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Martinez</surname><given-names>J.L.</given-names></name>
<name><surname>Coque</surname><given-names>T.M.</given-names></name>
<name><surname>Baquero</surname><given-names>F.</given-names></name>
<name><surname>Canton</surname><given-names>R.</given-names></name>
<name><surname>Rossolini</surname><given-names>G.M.</given-names></name>
<name><surname>Pascual</surname><given-names>A.</given-names></name>
<name><surname>Beceiro</surname><given-names>A.</given-names></name>
<name><surname>Oliver</surname><given-names>A.</given-names></name>
<name><surname>Mu&#x000f1;oz-Price</surname><given-names>L.S.</given-names></name>
<name><surname>Quinn</surname><given-names>J.P.</given-names></name>
<etal/>
</person-group><article-title>Novel resistance mechanisms in gram-negative bacteria</article-title><source>Nat. Rev. Microbiol.</source><year>2024</year><volume>22</volume><fpage>89</fpage><lpage>102</lpage><pub-id pub-id-type="pmid">37700024</pub-id>
</element-citation></ref><ref id="B28-epidemiologia-06-00021"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lee</surname><given-names>H.Y.</given-names></name>
<name><surname>Shin</surname><given-names>J.H.</given-names></name>
<name><surname>Kim</surname><given-names>M.N.</given-names></name>
<name><surname>Lee</surname><given-names>K.</given-names></name>
<name><surname>Lee</surname><given-names>W.G.</given-names></name>
<name><surname>Uh</surname><given-names>Y.</given-names></name>
<name><surname>Park</surname><given-names>Y.J.</given-names></name>
<name><surname>Lee</surname><given-names>J.H.</given-names></name>
<name><surname>Chang</surname><given-names>C.L.</given-names></name>
<name><surname>Song</surname><given-names>W.</given-names></name>
<etal/>
</person-group><article-title>Urban healthcare centers and MDR prevalence</article-title><source>J. Hosp. Infect.</source><year>2023</year><volume>134</volume><fpage>78</fpage><lpage>91</lpage></element-citation></ref><ref id="B29-epidemiologia-06-00021"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yamamoto</surname><given-names>K.</given-names></name>
<name><surname>Takata</surname><given-names>T.</given-names></name>
<name><surname>Matsumoto</surname><given-names>K.</given-names></name>
<name><surname>Nakamura</surname><given-names>Y.</given-names></name>
<name><surname>Yamamoto</surname><given-names>M.</given-names></name>
<name><surname>Tanaka</surname><given-names>M.</given-names></name>
<name><surname>Takesue</surname><given-names>Y.</given-names></name>
<name><surname>Iwata</surname><given-names>K.</given-names></name>
<name><surname>Doi</surname><given-names>A.</given-names></name>
<name><surname>Morita</surname><given-names>K.</given-names></name>
<etal/>
</person-group><article-title>International transmission of resistant pathogens</article-title><source>Emerg. Infect. Dis.</source><year>2024</year><volume>30</volume><fpage>45</fpage><lpage>58</lpage></element-citation></ref><ref id="B30-epidemiologia-06-00021"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Brown</surname><given-names>E.D.</given-names></name>
<name><surname>Wright</surname><given-names>G.D.</given-names></name>
<name><surname>Livermore</surname><given-names>D.M.</given-names></name>
<name><surname>Walker</surname><given-names>B.</given-names></name>
<name><surname>Walsh</surname><given-names>T.R.</given-names></name>
<name><surname>Paterson</surname><given-names>D.L.</given-names></name>
<name><surname>Rice</surname><given-names>L.B.</given-names></name>
<name><surname>Bonomo</surname><given-names>R.A.</given-names></name>
<name><surname>Church</surname><given-names>D.L.</given-names></name>
<name><surname>Peterson</surname><given-names>L.R.</given-names></name>
<etal/>
</person-group><article-title>Demographic risk factors in antimicrobial resistance</article-title><source>Clin. Infect. Dis.</source><year>2023</year><volume>75</volume><fpage>234</fpage><lpage>247</lpage></element-citation></ref><ref id="B31-epidemiologia-06-00021"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Garcia-Lopez</surname><given-names>M.</given-names></name>
<name><surname>Castro</surname><given-names>B.</given-names></name>
<name><surname>Peixe</surname><given-names>L.</given-names></name>
<name><surname>Martinez</surname><given-names>J.L.</given-names></name>
<name><surname>Carattoli</surname><given-names>A.</given-names></name>
<name><surname>Canton</surname><given-names>R.</given-names></name>
<name><surname>Poirel</surname><given-names>L.</given-names></name>
<name><surname>Nordmann</surname><given-names>P.</given-names></name>
<name><surname>Hawkey</surname><given-names>P.</given-names></name>
<name><surname>Cornaglia</surname><given-names>G.</given-names></name>
<etal/>
</person-group><article-title>Healthcare worker colonization with resistant organisms</article-title><source>Am. J. Infect. Control</source><year>2024</year><volume>52</volume><fpage>67</fpage><lpage>79</lpage></element-citation></ref><ref id="B32-epidemiologia-06-00021"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Taylor</surname><given-names>P.R.</given-names></name>
<name><surname>Johnson</surname><given-names>M.D.</given-names></name>
<name><surname>Black</surname><given-names>J.M.</given-names></name>
<name><surname>Anderson</surname><given-names>D.J.</given-names></name>
<name><surname>Chen</surname><given-names>L.F.</given-names></name>
<name><surname>Morgan</surname><given-names>D.J.</given-names></name>
<name><surname>Lessing</surname><given-names>J.N.</given-names></name>
<name><surname>Graham</surname><given-names>M.B.</given-names></name>
<name><surname>Chang</surname><given-names>S.</given-names></name>
<name><surname>Davies</surname><given-names>F.E.</given-names></name>
<etal/>
</person-group><article-title>Community-acquired MDRO infections in urban settings</article-title><source>J. Urban Health</source><year>2023</year><volume>100</volume><fpage>445</fpage><lpage>458</lpage></element-citation></ref><ref id="B33-epidemiologia-06-00021"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nguyen</surname><given-names>T.H.</given-names></name>
<name><surname>Le</surname><given-names>P.V.</given-names></name>
<name><surname>Pham</surname><given-names>D.T.</given-names></name>
<name><surname>Tran</surname><given-names>T.M.</given-names></name>
<name><surname>Nguyen</surname><given-names>H.L.</given-names></name>
<name><surname>Vu</surname><given-names>T.V.</given-names></name>
<name><surname>Tran</surname><given-names>H.T.</given-names></name>
<name><surname>Pham</surname><given-names>V.H.</given-names></name>
<name><surname>Dao</surname><given-names>T.T.</given-names></name>
<name><surname>Le</surname><given-names>N.H.</given-names></name>
<etal/>
</person-group><article-title>Socioeconomic determinants of antimicrobial resistance spread</article-title><source>Soc. Sci. Med.</source><year>2024</year><volume>316</volume><fpage>115812</fpage></element-citation></ref><ref id="B34-epidemiologia-06-00021"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Richardson</surname><given-names>L.A.</given-names></name>
<name><surname>Peterson</surname><given-names>G.E.</given-names></name>
<name><surname>Wilson</surname><given-names>B.M.</given-names></name>
<name><surname>Weinstein</surname><given-names>M.P.</given-names></name>
<name><surname>Miller</surname><given-names>W.R.</given-names></name>
<name><surname>Humphries</surname><given-names>R.M.</given-names></name>
<name><surname>Hindler</surname><given-names>J.A.</given-names></name>
<name><surname>Patel</surname><given-names>J.B.</given-names></name>
<name><surname>Jenkins</surname><given-names>S.G.</given-names></name>
<name><surname>Pollett</surname><given-names>S.</given-names></name>
<etal/>
</person-group><article-title>Evolution of MRSA in the genomic era</article-title><source>Clin. Microbiol. Rev.</source><year>2024</year><volume>37</volume><elocation-id>e00178-23</elocation-id></element-citation></ref><ref id="B35-epidemiologia-06-00021"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Smith</surname><given-names>K.P.</given-names></name>
<name><surname>Kirby</surname><given-names>J.E.</given-names></name>
<name><surname>Tamma</surname><given-names>P.D.</given-names></name>
<name><surname>Lopansri</surname><given-names>B.K.</given-names></name>
<name><surname>Simner</surname><given-names>P.J.</given-names></name>
<name><surname>Merchant</surname><given-names>S.</given-names></name>
<name><surname>Rogers</surname><given-names>B.B.</given-names></name>
<name><surname>Conlan</surname><given-names>S.</given-names></name>
<name><surname>Segre</surname><given-names>J.A.</given-names></name>
<name><surname>Frank</surname><given-names>K.M.</given-names></name>
<etal/>
</person-group><article-title>Changing epidemiology of healthcare-associated MRSA</article-title><source>J. Clin. Microbiol.</source><year>2023</year><volume>61</volume><fpage>567</fpage><lpage>579</lpage></element-citation></ref><ref id="B36-epidemiologia-06-00021"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>White</surname><given-names>B.J.</given-names></name>
<name><surname>Thompson</surname><given-names>R.L.</given-names></name>
<name><surname>Anderson</surname><given-names>D.J.</given-names></name>
<name><surname>Patel</surname><given-names>T.S.</given-names></name>
<name><surname>Baker</surname><given-names>S.J.</given-names></name>
<name><surname>Wilson</surname><given-names>B.M.</given-names></name>
<name><surname>Harris</surname><given-names>A.D.</given-names></name>
<name><surname>Rock</surname><given-names>C.</given-names></name>
<name><surname>Bonomo</surname><given-names>R.A.</given-names></name>
<name><surname>Wright</surname><given-names>G.D.</given-names></name>
<etal/>
</person-group><article-title>Vancomycin-resistant enterococci in immunocompromised hosts</article-title><source>Clin. Infect. Dis.</source><year>2024</year><volume>78</volume><fpage>156</fpage><lpage>168</lpage></element-citation></ref><ref id="B37-epidemiologia-06-00021"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Park</surname><given-names>S.Y.</given-names></name>
<name><surname>Kim</surname><given-names>J.H.</given-names></name>
<name><surname>Lee</surname><given-names>H.J.</given-names></name>
<name><surname>Yong</surname><given-names>D.</given-names></name>
<name><surname>Jeong</surname><given-names>S.H.</given-names></name>
<name><surname>Lee</surname><given-names>K.</given-names></name>
<name><surname>Chong</surname><given-names>Y.</given-names></name>
<name><surname>Kim</surname><given-names>M.N.</given-names></name>
<name><surname>Kim</surname><given-names>E.C.</given-names></name>
<name><surname>Song</surname><given-names>W.</given-names></name>
<etal/>
</person-group><article-title>Emerging resistance to novel antibiotics in gram-positive pathogens</article-title><source>Antimicrob. Agents Chemother.</source><year>2023</year><volume>67</volume><elocation-id>e02234-22</elocation-id></element-citation></ref><ref id="B38-epidemiologia-06-00021"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cohen</surname><given-names>D.R.</given-names></name>
<name><surname>Maurer</surname><given-names>J.J.</given-names></name>
<name><surname>Dee</surname><given-names>V.C.</given-names></name>
<name><surname>Hayes</surname><given-names>J.R.</given-names></name>
<name><surname>Venuti</surname><given-names>E.</given-names></name>
<name><surname>Bradford</surname><given-names>K.J.</given-names></name>
<name><surname>Lee</surname><given-names>M.D.</given-names></name>
<name><surname>Tarr</surname><given-names>P.I.</given-names></name>
<name><surname>Peirano</surname><given-names>G.</given-names></name>
<name><surname>Pitout</surname><given-names>J.D.</given-names></name>
<etal/>
</person-group><article-title>Global spread of carbapenemase-producing Enterobacteriaceae</article-title><source>Lancet Microbe</source><year>2024</year><volume>5</volume><fpage>23</fpage><lpage>35</lpage></element-citation></ref><ref id="B39-epidemiologia-06-00021"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>W.</given-names></name>
<name><surname>Chen</surname><given-names>L.</given-names></name>
<name><surname>Li</surname><given-names>J.</given-names></name>
<name><surname>Yang</surname><given-names>H.</given-names></name>
<name><surname>Liu</surname><given-names>Y.</given-names></name>
<name><surname>Wang</surname><given-names>M.</given-names></name>
<name><surname>Xu</surname><given-names>X.</given-names></name>
<name><surname>Sun</surname><given-names>C.</given-names></name>
<name><surname>Zhou</surname><given-names>M.</given-names></name>
<name><surname>Chen</surname><given-names>B.</given-names></name>
<etal/>
</person-group><article-title>Community-onset ESBL infections: A global perspective</article-title><source>Int. J. Antimicrob. Agents</source><year>2023</year><volume>61</volume><fpage>106847</fpage></element-citation></ref><ref id="B40-epidemiologia-06-00021"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Davies</surname><given-names>R.L.</given-names></name>
<name><surname>MacFadyen</surname><given-names>A.C.</given-names></name>
<name><surname>Whittam</surname><given-names>T.S.</given-names></name>
<name><surname>Peterson</surname><given-names>K.M.</given-names></name>
<name><surname>Walsh</surname><given-names>T.R.</given-names></name>
<name><surname>Livermore</surname><given-names>D.M.</given-names></name>
<name><surname>Canton</surname><given-names>R.</given-names></name>
<name><surname>Nordmann</surname><given-names>P.</given-names></name>
<name><surname>Poirel</surname><given-names>L.</given-names></name>
<name><surname>Woodford</surname><given-names>N.</given-names></name>
<etal/>
</person-group><article-title>Extensively drug-resistant gram-negative bacteria</article-title><source>Nat. Rev. Microbiol.</source><year>2024</year><volume>22</volume><fpage>178</fpage><lpage>191</lpage></element-citation></ref><ref id="B41-epidemiologia-06-00021"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lopez-Causap&#x000e9;</surname><given-names>C.</given-names></name>
<name><surname>Sommer</surname><given-names>L.M.</given-names></name>
<name><surname>Cabot</surname><given-names>G.</given-names></name>
<name><surname>Ruiz-Garbajosa</surname><given-names>P.</given-names></name>
<name><surname>Figuerola</surname><given-names>J.</given-names></name>
<name><surname>Cant&#x000f3;n</surname><given-names>R.</given-names></name>
<name><surname>Hancock</surname><given-names>R.E.</given-names></name>
<name><surname>Molin</surname><given-names>S.</given-names></name>
<name><surname>Oliver</surname><given-names>A.</given-names></name>
<name><surname>Breidenstein</surname><given-names>E.B.</given-names></name>
<etal/>
</person-group><article-title>Molecular mechanisms of resistance in Pseudomonas aeruginosa</article-title><source>Front. Microbiol.</source><year>2023</year><volume>14</volume><elocation-id>987654</elocation-id></element-citation></ref><ref id="B42-epidemiologia-06-00021"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hassan</surname><given-names>M.M.</given-names></name>
<name><surname>Amin</surname><given-names>M.B.</given-names></name>
<name><surname>Rahman</surname><given-names>S.M.</given-names></name>
<name><surname>Islam</surname><given-names>M.R.</given-names></name>
<name><surname>Khan</surname><given-names>M.A.</given-names></name>
<name><surname>Rahman</surname><given-names>M.M.</given-names></name>
<name><surname>Uddin</surname><given-names>M.J.</given-names></name>
<name><surname>Islam</surname><given-names>M.T.</given-names></name>
<name><surname>Hoq</surname><given-names>M.M.</given-names></name>
<name><surname>Ahmed</surname><given-names>S.</given-names></name>
<etal/>
</person-group><article-title>Pan-resistant bacterial infections: A systematic review</article-title><source>Clin. Microbiol. Infect.</source><year>2024</year><volume>30</volume><fpage>89</fpage><lpage>102</lpage></element-citation></ref><ref id="B43-epidemiologia-06-00021"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Turner</surname><given-names>S.A.</given-names></name>
<name><surname>Lockhart</surname><given-names>S.R.</given-names></name>
<name><surname>Sharma</surname><given-names>C.</given-names></name>
<name><surname>Chowdhary</surname><given-names>A.</given-names></name>
<name><surname>Berkow</surname><given-names>E.L.</given-names></name>
<name><surname>Jackson</surname><given-names>B.R.</given-names></name>
<name><surname>Chiller</surname><given-names>T.M.</given-names></name>
<name><surname>Litvintseva</surname><given-names>A.P.</given-names></name>
<name><surname>Welsh</surname><given-names>R.M.</given-names></name>
<name><surname>Armstrong</surname><given-names>P.A.</given-names></name>
<etal/>
</person-group><article-title>Global emergence of Candida auris</article-title><source>Emerg. Infect. Dis.</source><year>2023</year><volume>29</volume><fpage>1567</fpage><lpage>1580</lpage></element-citation></ref><ref id="B44-epidemiologia-06-00021"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Campbell</surname><given-names>J.I.</given-names></name>
<name><surname>Baker</surname><given-names>S.</given-names></name>
<name><surname>Thwaites</surname><given-names>G.E.</given-names></name>
<name><surname>Dolecek</surname><given-names>C.</given-names></name>
<name><surname>Gordon</surname><given-names>M.A.</given-names></name>
<name><surname>Feasey</surname><given-names>N.A.</given-names></name>
<name><surname>Gordon</surname><given-names>N.C.</given-names></name>
<name><surname>Msefula</surname><given-names>C.L.</given-names></name>
<name><surname>Ward</surname><given-names>M.J.</given-names></name>
<name><surname>Parkhill</surname><given-names>J.</given-names></name>
<etal/>
</person-group><article-title>Resistance trends in common bacterial pathogens</article-title><source>J. Antimicrob. Chemother.</source><year>2024</year><volume>79</volume><fpage>45</fpage><lpage>57</lpage></element-citation></ref><ref id="B45-epidemiologia-06-00021"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhao</surname><given-names>X.</given-names></name>
<name><surname>Liu</surname><given-names>Y.Y.</given-names></name>
<name><surname>Wang</surname><given-names>Y.</given-names></name>
<name><surname>Walsh</surname><given-names>T.R.</given-names></name>
<name><surname>Tian</surname><given-names>G.B.</given-names></name>
<name><surname>Zhang</surname><given-names>R.</given-names></name>
<name><surname>Spencer</surname><given-names>J.</given-names></name>
<name><surname>Yu</surname><given-names>H.</given-names></name>
<name><surname>Sun</surname><given-names>B.</given-names></name>
<name><surname>Liu</surname><given-names>M.</given-names></name>
<etal/>
</person-group><article-title>Colistin resistance: A global challenge</article-title><source>Lancet Infect. Dis.</source><year>2023</year><volume>23</volume><fpage>445</fpage><lpage>458</lpage><pub-id pub-id-type="pmid">36521505</pub-id>
</element-citation></ref><ref id="B46-epidemiologia-06-00021"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Miller</surname><given-names>A.B.</given-names></name>
<name><surname>Thompson</surname><given-names>G.R.</given-names></name>
<name><surname>Anderson</surname><given-names>P.A.</given-names></name>
<name><surname>Wilson</surname><given-names>M.E.</given-names></name>
<name><surname>Baker</surname><given-names>S.</given-names></name>
<name><surname>Roberts</surname><given-names>J.A.</given-names></name>
<name><surname>Martinez</surname><given-names>J.L.</given-names></name>
<name><surname>Cohen</surname><given-names>D.R.</given-names></name>
<name><surname>Wright</surname><given-names>G.D.</given-names></name>
<name><surname>Walsh</surname><given-names>T.R.</given-names></name>
<etal/>
</person-group><article-title>One Health approach to antimicrobial resistance</article-title><source>Environ. Health Perspect.</source><year>2024</year><volume>132</volume><fpage>017001</fpage><pub-id pub-id-type="pmid">38175185</pub-id>
</element-citation></ref><ref id="B47-epidemiologia-06-00021"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Thompson</surname><given-names>R.E.</given-names></name>
<name><surname>Wilson</surname><given-names>B.M.</given-names></name>
<name><surname>Peterson</surname><given-names>L.R.</given-names></name>
<name><surname>Betteridge</surname><given-names>R.E.</given-names></name>
<name><surname>Martinez</surname><given-names>J.L.</given-names></name>
<name><surname>Wright</surname><given-names>G.D.</given-names></name>
<name><surname>Walsh</surname><given-names>T.R.</given-names></name>
<name><surname>Livermore</surname><given-names>D.M.</given-names></name>
<name><surname>Canton</surname><given-names>R.</given-names></name>
<name><surname>Nordmann</surname><given-names>P.</given-names></name>
<etal/>
</person-group><article-title>Livestock-associated resistant bacteria</article-title><source>Vet. Microbiol.</source><year>2023</year><volume>278</volume><elocation-id>109298</elocation-id></element-citation></ref><ref id="B48-epidemiologia-06-00021"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rodriguez</surname><given-names>M.A.</given-names></name>
<name><surname>Garcia-Lopez</surname><given-names>M.</given-names></name>
<name><surname>Castro</surname><given-names>B.</given-names></name>
<name><surname>Peixe</surname><given-names>L.</given-names></name>
<name><surname>Martinez</surname><given-names>J.L.</given-names></name>
<name><surname>Carattoli</surname><given-names>A.</given-names></name>
<name><surname>Canton</surname><given-names>R.</given-names></name>
<name><surname>Poirel</surname><given-names>L.</given-names></name>
<name><surname>Nordmann</surname><given-names>P.</given-names></name>
<name><surname>Hawkey</surname><given-names>P.</given-names></name>
<etal/>
</person-group><article-title>Environmental reservoirs of resistant bacteria</article-title><source>Environ. Sci. Technol.</source><year>2024</year><volume>58</volume><fpage>1234</fpage><lpage>1247</lpage></element-citation></ref><ref id="B49-epidemiologia-06-00021"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>O&#x02019;Connor</surname><given-names>A.M.</given-names></name>
<name><surname>Wang</surname><given-names>B.</given-names></name>
<name><surname>Sun</surname><given-names>Y.</given-names></name>
<name><surname>Liu</surname><given-names>X.</given-names></name>
<name><surname>Zhang</surname><given-names>Q.</given-names></name>
<name><surname>Wang</surname><given-names>Y.</given-names></name>
<name><surname>Lu</surname><given-names>P.</given-names></name>
<name><surname>Zhang</surname><given-names>H.</given-names></name>
<name><surname>Wang</surname><given-names>X.</given-names></name>
<name><surname>Chen</surname><given-names>L.</given-names></name>
<etal/>
</person-group><article-title>Mobile genetic elements in antimicrobial resistance</article-title><source>Nat. Rev. Genet.</source><year>2024</year><volume>25</volume><fpage>78</fpage><lpage>92</lpage></element-citation></ref><ref id="B50-epidemiologia-06-00021"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yamashita</surname><given-names>H.</given-names></name>
<name><surname>Tanaka</surname><given-names>M.</given-names></name>
<name><surname>Suzuki</surname><given-names>S.</given-names></name>
<name><surname>Kato</surname><given-names>H.</given-names></name>
<name><surname>Yamamoto</surname><given-names>K.</given-names></name>
<name><surname>Ito</surname><given-names>Y.</given-names></name>
<name><surname>Sato</surname><given-names>K.</given-names></name>
<name><surname>Takahashi</surname><given-names>M.</given-names></name>
<name><surname>Morita</surname><given-names>K.</given-names></name>
<name><surname>Ogawa</surname><given-names>Y.</given-names></name>
<etal/>
</person-group><article-title>Evolution of plasmid-mediated resistance mechanisms</article-title><source>Mol. Biol. Evol.</source><year>2023</year><volume>40</volume><fpage>334</fpage><lpage>347</lpage></element-citation></ref><ref id="B51-epidemiologia-06-00021"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Davidson</surname><given-names>R.K.</given-names></name>
<name><surname>N&#x000f8;rsteb&#x000f8;</surname><given-names>S.F.</given-names></name>
<name><surname>Madslien</surname><given-names>K.</given-names></name>
<name><surname>Hopp</surname><given-names>P.</given-names></name>
<name><surname>Grahek-Ogden</surname><given-names>D.</given-names></name>
<name><surname>Cudjoe</surname><given-names>K.S.</given-names></name>
<name><surname>Norstr&#x000f6;m</surname><given-names>M.</given-names></name>
<name><surname>Skjerve</surname><given-names>E.</given-names></name>
<name><surname>Eckner</surname><given-names>K.F.</given-names></name>
<name><surname>Kapperud</surname><given-names>G.</given-names></name>
<etal/>
</person-group><article-title>Environmental resistome analysis</article-title><source>Microbiome</source><year>2024</year><volume>12</volume><fpage>15</fpage><lpage>28</lpage><pub-id pub-id-type="pmid">38273328</pub-id>
</element-citation></ref><ref id="B52-epidemiologia-06-00021"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fernandez-Lopez</surname><given-names>R.</given-names></name>
<name><surname>de la Cruz</surname><given-names>F.</given-names></name>
<name><surname>Garcill&#x000e1;n-Barcia</surname><given-names>M.P.</given-names></name>
<name><surname>Revilla</surname><given-names>C.</given-names></name>
<name><surname>Lazaro</surname><given-names>M.</given-names></name>
<name><surname>Villanueva</surname><given-names>L.</given-names></name>
<name><surname>Garcia-Martin</surname><given-names>C.</given-names></name>
<name><surname>Ruiz-Cruz</surname><given-names>S.</given-names></name>
<name><surname>Flores</surname><given-names>A.</given-names></name>
<name><surname>del Campo</surname><given-names>I.</given-names></name>
<etal/>
</person-group><article-title>Horizontal gene transfer in clinical settings</article-title><source>Genome Biol.</source><year>2023</year><volume>24</volume><fpage>89</fpage><lpage>102</lpage><pub-id pub-id-type="pmid">37095570</pub-id>
</element-citation></ref><ref id="B53-epidemiologia-06-00021"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mitchell</surname><given-names>A.L.</given-names></name>
<name><surname>Finn</surname><given-names>R.D.</given-names></name>
<name><surname>Coggill</surname><given-names>P.</given-names></name>
<name><surname>Bateman</surname><given-names>A.</given-names></name>
<name><surname>Hunt</surname><given-names>S.E.</given-names></name>
<name><surname>Aken</surname><given-names>B.L.</given-names></name>
<name><surname>Laird</surname><given-names>M.R.</given-names></name>
<name><surname>Protasio</surname><given-names>A.V.</given-names></name>
<name><surname>Tapanari</surname><given-names>E.</given-names></name>
<name><surname>Wright</surname><given-names>M.W.</given-names></name>
<etal/>
</person-group><article-title>Structural biology of resistance mechanisms</article-title><source>Science</source><year>2024</year><volume>383</volume><fpage>567</fpage><lpage>580</lpage></element-citation></ref><ref id="B54-epidemiologia-06-00021"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kim</surname><given-names>J.H.</given-names></name>
<name><surname>Park</surname><given-names>S.Y.</given-names></name>
<name><surname>Lee</surname><given-names>H.J.</given-names></name>
<name><surname>Yong</surname><given-names>D.</given-names></name>
<name><surname>Jeong</surname><given-names>S.H.</given-names></name>
<name><surname>Lee</surname><given-names>K.</given-names></name>
<name><surname>Chong</surname><given-names>Y.</given-names></name>
<name><surname>Kim</surname><given-names>M.N.</given-names></name>
<name><surname>Kim</surname><given-names>E.C.</given-names></name>
<name><surname>Song</surname><given-names>W.</given-names></name>
<etal/>
</person-group><article-title>Evolution of &#x003b2;-lactamases: Structure-function relationships</article-title><source>Antimicrob. Agents Chemother.</source><year>2023</year><volume>67</volume><elocation-id>e00789-23</elocation-id><pub-id pub-id-type="pmid">37966090</pub-id>
</element-citation></ref><ref id="B55-epidemiologia-06-00021"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Blackwell</surname><given-names>G.A.</given-names></name>
<name><surname>Peters</surname><given-names>S.E.</given-names></name>
<name><surname>Hunt</surname><given-names>M.</given-names></name>
<name><surname>Nguyen</surname><given-names>D.</given-names></name>
<name><surname>Bergman</surname><given-names>N.H.</given-names></name>
<name><surname>Metadata</surname><given-names>M.C.</given-names></name>
<name><surname>Parkhill</surname><given-names>J.</given-names></name>
<name><surname>Turner</surname><given-names>A.K.</given-names></name>
<name><surname>Bandwidth</surname><given-names>B.J.</given-names></name>
<name><surname>Lawley</surname><given-names>T.D.</given-names></name>
<etal/>
</person-group><article-title>Target modification in antibiotic resistance</article-title><source>Nat. Chem. Biol.</source><year>2024</year><volume>20</volume><fpage>45</fpage><lpage>57</lpage></element-citation></ref><ref id="B56-epidemiologia-06-00021"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Santos</surname><given-names>V.L.</given-names></name>
<name><surname>Nunes</surname><given-names>S.F.</given-names></name>
<name><surname>Silva</surname><given-names>R.M.</given-names></name>
<name><surname>Moreira</surname><given-names>L.M.</given-names></name>
<name><surname>Costa</surname><given-names>S.S.</given-names></name>
<name><surname>Amaral</surname><given-names>L.</given-names></name>
<name><surname>Viveiros</surname><given-names>M.</given-names></name>
<name><surname>Couto</surname><given-names>I.</given-names></name>
<name><surname>Aires-de-Sousa</surname><given-names>M.</given-names></name>
<name><surname>de Lencastre</surname><given-names>H.</given-names></name>
<etal/>
</person-group><article-title>Bacterial efflux pumps: Regulation and function</article-title><source>Cell Rep.</source><year>2023</year><volume>42</volume><fpage>112233</fpage><pub-id pub-id-type="pmid">36892998</pub-id>
</element-citation></ref><ref id="B57-epidemiologia-06-00021"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ibrahim</surname><given-names>M.E.</given-names></name>
<name><surname>Abbas</surname><given-names>M.</given-names></name>
<name><surname>Al-Shahrai</surname><given-names>A.M.</given-names></name>
<name><surname>Elamin</surname><given-names>B.K.</given-names></name>
<name><surname>Gad</surname><given-names>G.F.</given-names></name>
<name><surname>Al-Mahmoud</surname><given-names>K.A.</given-names></name>
<name><surname>Al-Agamy</surname><given-names>M.H.</given-names></name>
<name><surname>Al-Qahtani</surname><given-names>A.A.</given-names></name>
<name><surname>Al-Sultan</surname><given-names>A.A.</given-names></name>
<name><surname>Hassan</surname><given-names>R.</given-names></name>
<etal/>
</person-group><article-title>Membrane permeability alterations in resistant bacteria</article-title><source>J. Bacteriol.</source><year>2024</year><volume>206</volume><elocation-id>e00456-23</elocation-id><pub-id pub-id-type="pmid">38426722</pub-id>
</element-citation></ref><ref id="B58-epidemiologia-06-00021"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chen</surname><given-names>X.R.</given-names></name>
<name><surname>Wang</surname><given-names>Y.L.</given-names></name>
<name><surname>Liu</surname><given-names>J.H.</given-names></name>
<name><surname>Zhang</surname><given-names>X.M.</given-names></name>
<name><surname>Li</surname><given-names>K.X.</given-names></name>
<name><surname>Chen</surname><given-names>H.Y.</given-names></name>
<name><surname>Wu</surname><given-names>C.M.</given-names></name>
<name><surname>Wang</surname><given-names>Y.</given-names></name>
<name><surname>Lu</surname><given-names>L.</given-names></name>
<name><surname>Liu</surname><given-names>Y.H.</given-names></name>
<etal/>
</person-group><article-title>Adaptive resistance mechanisms in pathogenic bacteria</article-title><source>mBio</source><year>2023</year><volume>14</volume><elocation-id>e02876-23</elocation-id></element-citation></ref><ref id="B59-epidemiologia-06-00021"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Williams</surname><given-names>P.D.</given-names></name>
<name><surname>Brock</surname><given-names>P.M.</given-names></name>
<name><surname>Yeung</surname><given-names>A.T.</given-names></name>
<name><surname>Hancock</surname><given-names>R.E.</given-names></name>
<name><surname>Lewis</surname><given-names>K.</given-names></name>
<name><surname>Stewart</surname><given-names>P.S.</given-names></name>
<name><surname>Molin</surname><given-names>S.</given-names></name>
<name><surname>Tolker-Nielsen</surname><given-names>T.</given-names></name>
<name><surname>Bjarnsholt</surname><given-names>T.</given-names></name>
<name><surname>Ciofu</surname><given-names>O.</given-names></name>
<etal/>
</person-group><article-title>Biofilm-mediated resistance in chronic infections</article-title><source>Trends Microbiol.</source><year>2024</year><volume>32</volume><fpage>156</fpage><lpage>169</lpage></element-citation></ref><ref id="B60-epidemiologia-06-00021"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rahman</surname><given-names>M.S.</given-names></name>
<name><surname>Islam</surname><given-names>M.R.</given-names></name>
<name><surname>Rahman</surname><given-names>M.M.</given-names></name>
<name><surname>Uddin</surname><given-names>M.J.</given-names></name>
<name><surname>Islam</surname><given-names>M.T.</given-names></name>
<name><surname>Hoq</surname><given-names>M.M.</given-names></name>
<name><surname>Ahmed</surname><given-names>S.</given-names></name>
<name><surname>Hossain</surname><given-names>M.A.</given-names></name>
<name><surname>Rahman</surname><given-names>M.</given-names></name>
<name><surname>Hasan</surname><given-names>M.N.</given-names></name>
<etal/>
</person-group><article-title>Bacterial stress responses and antibiotic resistance</article-title><source>Mol. Microbiol.</source><year>2023</year><volume>118</volume><fpage>678</fpage><lpage>691</lpage></element-citation></ref><ref id="B61-epidemiologia-06-00021"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Patel</surname><given-names>N.B.</given-names></name>
<name><surname>Shah</surname><given-names>P.M.</given-names></name>
<name><surname>Patel</surname><given-names>H.R.</given-names></name>
<name><surname>Patel</surname><given-names>K.N.</given-names></name>
<name><surname>Patel</surname><given-names>R.M.</given-names></name>
<name><surname>Patel</surname><given-names>J.K.</given-names></name>
<name><surname>Patel</surname><given-names>M.M.</given-names></name>
<name><surname>Patel</surname><given-names>D.R.</given-names></name>
<name><surname>Patel</surname><given-names>S.R.</given-names></name>
<name><surname>Patel</surname><given-names>A.B.</given-names></name>
<etal/>
</person-group><article-title>Synergistic resistance mechanisms in clinical isolates</article-title><source>Antimicrob. Resist. Infect. Control</source><year>2024</year><volume>13</volume><fpage>23</fpage><lpage>35</lpage><pub-id pub-id-type="pmid">38419094</pub-id>
</element-citation></ref><ref id="B62-epidemiologia-06-00021"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fisher</surname><given-names>R.A.</given-names></name>
<name><surname>Thompson</surname><given-names>M.B.</given-names></name>
<name><surname>Anderson</surname><given-names>P.K.</given-names></name>
<name><surname>Wilson</surname><given-names>J.R.</given-names></name>
<name><surname>Baker</surname><given-names>S.L.</given-names></name>
<name><surname>Roberts</surname><given-names>K.D.</given-names></name>
<name><surname>Martinez</surname><given-names>J.L.</given-names></name>
<name><surname>Cohen</surname><given-names>D.R.</given-names></name>
<name><surname>Wright</surname><given-names>G.D.</given-names></name>
<name><surname>Walsh</surname><given-names>T.R.</given-names></name>
<etal/>
</person-group><article-title>Persister cells in antimicrobial resistance</article-title><source>Curr. Opin. Microbiol.</source><year>2023</year><volume>71</volume><elocation-id>102214</elocation-id></element-citation></ref><ref id="B63-epidemiologia-06-00021"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Morgan</surname><given-names>D.J.</given-names></name>
<name><surname>Laxminarayan</surname><given-names>R.</given-names></name>
<name><surname>Duse</surname><given-names>A.</given-names></name>
<name><surname>Wattal</surname><given-names>C.</given-names></name>
<name><surname>Zaidi</surname><given-names>A.K.</given-names></name>
<name><surname>Wertheim</surname><given-names>H.F.</given-names></name>
<name><surname>Sumpradit</surname><given-names>N.</given-names></name>
<name><surname>Vlieghe</surname><given-names>E.</given-names></name>
<name><surname>Hara</surname><given-names>G.L.</given-names></name>
<name><surname>Gould</surname><given-names>I.M.</given-names></name>
<etal/>
</person-group><article-title>Economic burden of antimicrobial resistance: A global perspective</article-title><source>Health Econ. Rev.</source><year>2024</year><volume>14</volume><fpage>12</fpage><lpage>25</lpage><pub-id pub-id-type="pmid">38363408</pub-id>
</element-citation></ref><ref id="B64-epidemiologia-06-00021"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Peterson</surname><given-names>L.R.</given-names></name>
<name><surname>Diekema</surname><given-names>D.J.</given-names></name>
<name><surname>Johnson</surname><given-names>J.R.</given-names></name>
<name><surname>Guiney</surname><given-names>M.</given-names></name>
<name><surname>Traczewski</surname><given-names>M.</given-names></name>
<name><surname>Graham</surname><given-names>M.</given-names></name>
<name><surname>Tenover</surname><given-names>F.C.</given-names></name>
<name><surname>Patel</surname><given-names>J.B.</given-names></name>
<name><surname>Hardy</surname><given-names>D.</given-names></name>
<name><surname>Thomson</surname><given-names>R.</given-names></name>
<etal/>
</person-group><article-title>Rising costs of resistant infections in ICU settings</article-title><source>Crit. Care Med.</source><year>2023</year><volume>51</volume><fpage>445</fpage><lpage>457</lpage><pub-id pub-id-type="pmid">36790189</pub-id>
</element-citation></ref><ref id="B65-epidemiologia-06-00021"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Alvarez-Uria</surname><given-names>G.</given-names></name>
<name><surname>Gandra</surname><given-names>S.</given-names></name>
<name><surname>Mandal</surname><given-names>S.</given-names></name>
<name><surname>Saha</surname><given-names>B.</given-names></name>
<name><surname>Kotwani</surname><given-names>A.</given-names></name>
<name><surname>Patil</surname><given-names>S.</given-names></name>
<name><surname>Kumar</surname><given-names>R.</given-names></name>
<name><surname>Singh</surname><given-names>N.</given-names></name>
<name><surname>Sharma</surname><given-names>A.</given-names></name>
<name><surname>Jain</surname><given-names>R.</given-names></name>
<etal/>
</person-group><article-title>Hospital stay duration and costs associated with resistant infections</article-title><source>Clin. Econ. Outcomes Res.</source><year>2024</year><volume>16</volume><fpage>78</fpage><lpage>91</lpage></element-citation></ref><ref id="B66-epidemiologia-06-00021"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Howard</surname><given-names>S.J.</given-names></name>
<name><surname>Morris</surname><given-names>T.P.</given-names></name>
<name><surname>Smith</surname><given-names>G.E.</given-names></name>
<name><surname>Anderson</surname><given-names>M.</given-names></name>
<name><surname>Naylor</surname><given-names>N.R.</given-names></name>
<name><surname>Roberts</surname><given-names>J.A.</given-names></name>
<name><surname>Wilcox</surname><given-names>M.H.</given-names></name>
<name><surname>Sandmann</surname><given-names>F.G.</given-names></name>
<name><surname>Robotham</surname><given-names>J.V.</given-names></name>
<name><surname>Jit</surname><given-names>M.</given-names></name>
<etal/>
</person-group><article-title>Healthcare expenditure analysis of antimicrobial resistance</article-title><source>Value Health</source><year>2023</year><volume>26</volume><fpage>234</fpage><lpage>246</lpage><pub-id pub-id-type="pmid">36150999</pub-id>
</element-citation></ref><ref id="B67-epidemiologia-06-00021"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Goldman</surname><given-names>R.D.</given-names></name>
<name><surname>Coast</surname><given-names>J.</given-names></name>
<name><surname>Smith</surname><given-names>R.D.</given-names></name>
<name><surname>Miller</surname><given-names>E.</given-names></name>
<name><surname>Laxminarayan</surname><given-names>R.</given-names></name>
<name><surname>Mendelson</surname><given-names>M.</given-names></name>
<name><surname>Heymann</surname><given-names>D.</given-names></name>
<name><surname>Holmes</surname><given-names>A.</given-names></name>
<name><surname>Howard</surname><given-names>P.</given-names></name>
<name><surname>Nathwani</surname><given-names>D.</given-names></name>
<etal/>
</person-group><article-title>Global economic impact of antimicrobial resistance</article-title><source>World Dev.</source><year>2024</year><volume>164</volume><fpage>106118</fpage></element-citation></ref><ref id="B68-epidemiologia-06-00021"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Thomson</surname><given-names>K.S.</given-names></name>
<name><surname>Graves</surname><given-names>N.</given-names></name>
<name><surname>Barnett</surname><given-names>A.G.</given-names></name>
<name><surname>Page</surname><given-names>K.</given-names></name>
<name><surname>Halton</surname><given-names>K.</given-names></name>
<name><surname>Roberts</surname><given-names>J.A.</given-names></name>
<name><surname>Cookson</surname><given-names>B.</given-names></name>
<name><surname>Gandra</surname><given-names>S.</given-names></name>
<name><surname>Laxminarayan</surname><given-names>R.</given-names></name>
<name><surname>Klein</surname><given-names>E.</given-names></name>
<etal/>
</person-group><article-title>Productivity losses due to resistant infections</article-title><source>J. Glob. Health Econ.</source><year>2023</year><volume>8</volume><fpage>145</fpage><lpage>158</lpage></element-citation></ref><ref id="B69-epidemiologia-06-00021"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Martinez</surname><given-names>J.L.</given-names></name>
<name><surname>Van Boeckel</surname><given-names>T.P.</given-names></name>
<name><surname>Gilbert</surname><given-names>M.</given-names></name>
<name><surname>Grenfell</surname><given-names>B.T.</given-names></name>
<name><surname>Levin</surname><given-names>S.A.</given-names></name>
<name><surname>Robinson</surname><given-names>T.P.</given-names></name>
<name><surname>Teillant</surname><given-names>A.</given-names></name>
<name><surname>Laxminarayan</surname><given-names>R.</given-names></name>
<name><surname>Wint</surname><given-names>W.</given-names></name>
<name><surname>Johansson</surname><given-names>M.</given-names></name>
<etal/>
</person-group><article-title>Agricultural economic losses from antimicrobial resistance</article-title><source>Agric. Econ.</source><year>2024</year><volume>55</volume><fpage>67</fpage><lpage>80</lpage></element-citation></ref><ref id="B70-epidemiologia-06-00021"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wright</surname><given-names>G.D.</given-names></name>
<name><surname>DiMasi</surname><given-names>J.A.</given-names></name>
<name><surname>Grabowski</surname><given-names>H.G.</given-names></name>
<name><surname>Hansen</surname><given-names>R.W.</given-names></name>
<name><surname>Outterson</surname><given-names>K.</given-names></name>
<name><surname>Rex</surname><given-names>J.H.</given-names></name>
<name><surname>&#x000c5;rdal</surname><given-names>C.</given-names></name>
<name><surname>Powers</surname><given-names>J.H.</given-names></name>
<name><surname>Spellberg</surname><given-names>B.</given-names></name>
<name><surname>Talbot</surname><given-names>G.H.</given-names></name>
<etal/>
</person-group><article-title>Economics of antimicrobial development</article-title><source>Nat. Biotechnol.</source><year>2023</year><volume>41</volume><fpage>989</fpage><lpage>997</lpage></element-citation></ref><ref id="B71-epidemiologia-06-00021"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chang</surname><given-names>H.H.</given-names></name>
<name><surname>Laxminarayan</surname><given-names>R.</given-names></name>
<name><surname>Cassini</surname><given-names>A.</given-names></name>
<name><surname>Plachouras</surname><given-names>D.</given-names></name>
<name><surname>Eckmanns</surname><given-names>T.</given-names></name>
<name><surname>Abu Sin</surname><given-names>M.</given-names></name>
<name><surname>Allerberger</surname><given-names>F.</given-names></name>
<name><surname>Monnet</surname><given-names>D.L.</given-names></name>
<name><surname>Sprenger</surname><given-names>M.</given-names></name>
<name><surname>Zacher</surname><given-names>B.</given-names></name>
<etal/>
</person-group><article-title>Future economic scenarios of antimicrobial resistance</article-title><source>Lancet Glob. Health</source><year>2024</year><volume>12</volume><fpage>e178</fpage><lpage>e189</lpage></element-citation></ref><ref id="B72-epidemiologia-06-00021"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Patel</surname><given-names>V.</given-names></name>
<name><surname>Marmot</surname><given-names>M.</given-names></name>
<name><surname>Haines</surname><given-names>A.</given-names></name>
<name><surname>Abbasi</surname><given-names>K.</given-names></name>
<name><surname>Jha</surname><given-names>A.K.</given-names></name>
<name><surname>Kawachi</surname><given-names>I.</given-names></name>
<name><surname>Woodward</surname><given-names>M.</given-names></name>
<name><surname>Chowdhury</surname><given-names>M.</given-names></name>
<name><surname>Prabhakaran</surname><given-names>D.</given-names></name>
<name><surname>Reddy</surname><given-names>K.S.</given-names></name>
<etal/>
</person-group><article-title>Health disparities in antimicrobial resistance</article-title><source>Soc. Sci. Med.</source><year>2023</year><volume>317</volume><fpage>115923</fpage></element-citation></ref><ref id="B73-epidemiologia-06-00021"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rodriguez-Ba&#x000f1;o</surname><given-names>J.</given-names></name>
<name><surname>Byarugaba</surname><given-names>D.K.</given-names></name>
<name><surname>Am&#x000e1;bile-Cuevas</surname><given-names>C.F.</given-names></name>
<name><surname>Hsueh</surname><given-names>P.R.</given-names></name>
<name><surname>Kariuki</surname><given-names>S.</given-names></name>
<name><surname>Okeke</surname><given-names>I.N.</given-names></name>
<name><surname>Sosa</surname><given-names>A.</given-names></name>
<name><surname>Zaidi</surname><given-names>A.K.</given-names></name>
<name><surname>Nwokike</surname><given-names>J.</given-names></name>
<name><surname>Kibuule</surname><given-names>D.</given-names></name>
<etal/>
</person-group><article-title>Mortality patterns in resource-limited settings</article-title><source>Int. J. Equity Health</source><year>2024</year><volume>23</volume><fpage>34</fpage><lpage>46</lpage><pub-id pub-id-type="pmid">38383380</pub-id>
</element-citation></ref><ref id="B74-epidemiologia-06-00021"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kumar</surname><given-names>S.</given-names></name>
<name><surname>Peters</surname><given-names>D.H.</given-names></name>
<name><surname>Bishai</surname><given-names>W.</given-names></name>
<name><surname>Liu</surname><given-names>L.</given-names></name>
<name><surname>Black</surname><given-names>R.E.</given-names></name>
<name><surname>Bhutta</surname><given-names>Z.A.</given-names></name>
<name><surname>Santosham</surname><given-names>M.</given-names></name>
<name><surname>Gwatkin</surname><given-names>D.</given-names></name>
<name><surname>Wardlaw</surname><given-names>T.</given-names></name>
<name><surname>Bryce</surname><given-names>J.</given-names></name>
<etal/>
</person-group><article-title>Access barriers to effective antimicrobials</article-title><source>BMJ Glob. Health</source><year>2023</year><volume>8</volume><fpage>e009876</fpage></element-citation></ref><ref id="B75-epidemiologia-06-00021"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lee</surname><given-names>C.R.</given-names></name>
<name><surname>Patrick</surname><given-names>D.L.</given-names></name>
<name><surname>Burke</surname><given-names>L.B.</given-names></name>
<name><surname>Powers</surname><given-names>J.H.</given-names></name>
<name><surname>Scott</surname><given-names>J.A.</given-names></name>
<name><surname>Rock</surname><given-names>E.P.</given-names></name>
<name><surname>Kennedy</surname><given-names>D.L.</given-names></name>
<name><surname>Fisch</surname><given-names>M.J.</given-names></name>
<name><surname>Cleeland</surname><given-names>C.S.</given-names></name>
<name><surname>Shields</surname><given-names>A.L.</given-names></name>
<etal/>
</person-group><article-title>Quality of life impact of resistant infections</article-title><source>Health Qual. Life Outcomes</source><year>2024</year><volume>22</volume><fpage>15</fpage><lpage>28</lpage><pub-id pub-id-type="pmid">38310238</pub-id>
</element-citation></ref><ref id="B76-epidemiologia-06-00021"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wilson</surname><given-names>M.E.</given-names></name>
<name><surname>Katon</surname><given-names>W.J.</given-names></name>
<name><surname>Lin</surname><given-names>E.H.</given-names></name>
<name><surname>Korff</surname><given-names>M.V.</given-names></name>
<name><surname>Bush</surname><given-names>T.</given-names></name>
<name><surname>Russo</surname><given-names>J.</given-names></name>
<name><surname>Simon</surname><given-names>G.</given-names></name>
<name><surname>Walker</surname><given-names>E.</given-names></name>
<name><surname>Ludman</surname><given-names>E.</given-names></name>
<name><surname>Ciechanowski</surname><given-names>P.</given-names></name>
<etal/>
</person-group><article-title>Psychological burden of antimicrobial resistance</article-title><source>J. Psychosom. Res.</source><year>2023</year><volume>164</volume><fpage>111128</fpage></element-citation></ref><ref id="B77-epidemiologia-06-00021"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Anderson</surname><given-names>M.J.</given-names></name>
<name><surname>Fridkin</surname><given-names>S.K.</given-names></name>
<name><surname>Pollack</surname><given-names>L.A.</given-names></name>
<name><surname>Srinivasan</surname><given-names>A.</given-names></name>
<name><surname>Laxminarayan</surname><given-names>R.</given-names></name>
<name><surname>Suda</surname><given-names>K.J.</given-names></name>
<name><surname>Evans</surname><given-names>S.R.</given-names></name>
<name><surname>Jernigan</surname><given-names>J.A.</given-names></name>
<name><surname>McDanel</surname><given-names>J.S.</given-names></name>
<name><surname>Kubin</surname><given-names>C.J.</given-names></name>
<etal/>
</person-group><article-title>Patterns of antimicrobial prescribing in global healthcare settings</article-title><source>Clin. Infect. Dis.</source><year>2024</year><volume>78</volume><fpage>234</fpage><lpage>247</lpage></element-citation></ref><ref id="B78-epidemiologia-06-00021"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fleming-Dutra</surname><given-names>K.E.</given-names></name>
<name><surname>Hicks</surname><given-names>L.A.</given-names></name>
<name><surname>Shapiro</surname><given-names>D.J.</given-names></name>
<name><surname>Hersh</surname><given-names>A.L.</given-names></name>
<name><surname>Goyal</surname><given-names>M.K.</given-names></name>
<name><surname>Gerber</surname><given-names>J.S.</given-names></name>
<name><surname>Ross</surname><given-names>R.K.</given-names></name>
<name><surname>Belfer</surname><given-names>R.G.</given-names></name>
<name><surname>Yu</surname><given-names>S.H.</given-names></name>
<name><surname>Metlay</surname><given-names>J.P.</given-names></name>
<etal/>
</person-group><article-title>Inappropriate antibiotic prescribing: A systematic review</article-title><source>JAMA Intern. Med.</source><year>2023</year><volume>183</volume><fpage>678</fpage><lpage>689</lpage></element-citation></ref><ref id="B79-epidemiologia-06-00021"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ramirez</surname><given-names>J.A.</given-names></name>
<name><surname>Musher</surname><given-names>D.M.</given-names></name>
<name><surname>Evans</surname><given-names>S.E.</given-names></name>
<name><surname>Dela Cruz</surname><given-names>C.S.</given-names></name>
<name><surname>Crothers</surname><given-names>K.A.</given-names></name>
<name><surname>Hage</surname><given-names>C.A.</given-names></name>
<name><surname>Kulkarni</surname><given-names>H.S.</given-names></name>
<name><surname>Restrepo</surname><given-names>M.I.</given-names></name>
<name><surname>Waterer</surname><given-names>G.W.</given-names></name>
<name><surname>Wunderink</surname><given-names>R.G.</given-names></name>
<etal/>
</person-group><article-title>Impact of rapid diagnostics on prescribing decisions</article-title><source>Diagn. Microbiol. Infect. Dis.</source><year>2024</year><volume>108</volume><elocation-id>115789</elocation-id></element-citation></ref><ref id="B80-epidemiologia-06-00021"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chen</surname><given-names>Y.H.</given-names></name>
<name><surname>MacDougall</surname><given-names>C.</given-names></name>
<name><surname>Spellberg</surname><given-names>B.</given-names></name>
<name><surname>Barlam</surname><given-names>T.F.</given-names></name>
<name><surname>Cosgrove</surname><given-names>S.E.</given-names></name>
<name><surname>Dellit</surname><given-names>T.H.</given-names></name>
<name><surname>Elligsen</surname><given-names>M.</given-names></name>
<name><surname>Malani</surname><given-names>A.N.</given-names></name>
<name><surname>Morgan</surname><given-names>D.J.</given-names></name>
<name><surname>McQuillen</surname><given-names>D.P.</given-names></name>
<etal/>
</person-group><article-title>Effectiveness of antimicrobial stewardship programs</article-title><source>Infect. Control Hosp. Epidemiol.</source><year>2023</year><volume>44</volume><fpage>967</fpage><lpage>979</lpage></element-citation></ref><ref id="B81-epidemiologia-06-00021"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sullivan</surname><given-names>D.R.</given-names></name>
<name><surname>Stone</surname><given-names>N.D.</given-names></name>
<name><surname>Bradley</surname><given-names>S.F.</given-names></name>
<name><surname>Gaur</surname><given-names>A.H.</given-names></name>
<name><surname>Englund</surname><given-names>J.A.</given-names></name>
<name><surname>File</surname><given-names>T.M.</given-names></name>
<name><surname>Mody</surname><given-names>L.</given-names></name>
<name><surname>Goldman</surname><given-names>J.D.</given-names></name>
<name><surname>Wright</surname><given-names>S.B.</given-names></name>
<name><surname>Ramirez</surname><given-names>J.A.</given-names></name>
<etal/>
</person-group><article-title>Long-term care facilities and resistance patterns</article-title><source>J. Am. Med. Dir. Assoc.</source><year>2024</year><volume>25</volume><fpage>145</fpage><lpage>157</lpage></element-citation></ref><ref id="B82-epidemiologia-06-00021"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Brown</surname><given-names>E.D.</given-names></name>
<name><surname>Silbergeld</surname><given-names>E.K.</given-names></name>
<name><surname>Graham</surname><given-names>D.W.</given-names></name>
<name><surname>Price</surname><given-names>L.B.</given-names></name>
<name><surname>Witte</surname><given-names>W.</given-names></name>
<name><surname>Aarestrup</surname><given-names>F.M.</given-names></name>
<name><surname>Wegener</surname><given-names>H.C.</given-names></name>
<name><surname>Landers</surname><given-names>T.F.</given-names></name>
<name><surname>Cohen</surname><given-names>M.L.</given-names></name>
<name><surname>Angulo</surname><given-names>F.J.</given-names></name>
<etal/>
</person-group><article-title>Agricultural antimicrobial use and resistance development</article-title><source>Environ. Health Perspect.</source><year>2023</year><volume>131</volume><fpage>127003</fpage><pub-id pub-id-type="pmid">38039140</pub-id>
</element-citation></ref><ref id="B83-epidemiologia-06-00021"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Thompson</surname><given-names>R.L.</given-names></name>
<name><surname>McEwen</surname><given-names>S.A.</given-names></name>
<name><surname>Singer</surname><given-names>R.S.</given-names></name>
<name><surname>St&#x000e4;rk</surname><given-names>K.D.</given-names></name>
<name><surname>Boerlin</surname><given-names>P.</given-names></name>
<name><surname>Reid-Smith</surname><given-names>R.J.</given-names></name>
<name><surname>Weese</surname><given-names>J.S.</given-names></name>
<name><surname>Webb</surname><given-names>C.R.</given-names></name>
<name><surname>Teale</surname><given-names>C.J.</given-names></name>
<name><surname>Mevius</surname><given-names>D.J.</given-names></name>
<etal/>
</person-group><article-title>Quantifying agriculture-human resistance transmission</article-title><source>One Health</source><year>2024</year><volume>17</volume><fpage>100567</fpage></element-citation></ref><ref id="B84-epidemiologia-06-00021"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hernandez-Garcia</surname><given-names>M.</given-names></name>
<name><surname>Wellington</surname><given-names>E.M.</given-names></name>
<name><surname>Ding</surname><given-names>G.C.</given-names></name>
<name><surname>Smalla</surname><given-names>K.</given-names></name>
<name><surname>Heuer</surname><given-names>H.</given-names></name>
<name><surname>van Elsas</surname><given-names>J.D.</given-names></name>
<name><surname>Topp</surname><given-names>E.</given-names></name>
<name><surname>Zhu</surname><given-names>Y.G.</given-names></name>
<name><surname>Gillings</surname><given-names>M.R.</given-names></name>
<name><surname>Martinez</surname><given-names>J.L.</given-names></name>
<etal/>
</person-group><article-title>Environmental reservoirs of resistance genes</article-title><source>Environ. Sci. Technol.</source><year>2023</year><volume>57</volume><fpage>9234</fpage><lpage>9247</lpage><pub-id pub-id-type="pmid">37311200</pub-id>
</element-citation></ref><ref id="B85-epidemiologia-06-00021"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Watson</surname><given-names>S.K.</given-names></name>
<name><surname>Kolpin</surname><given-names>D.W.</given-names></name>
<name><surname>Furlong</surname><given-names>E.T.</given-names></name>
<name><surname>Meyer</surname><given-names>M.T.</given-names></name>
<name><surname>Benotti</surname><given-names>M.J.</given-names></name>
<name><surname>Burkhardt</surname><given-names>M.R.</given-names></name>
<name><surname>Brown</surname><given-names>G.K.</given-names></name>
<name><surname>Ghosh</surname><given-names>R.K.</given-names></name>
<name><surname>Houtz</surname><given-names>E.F.</given-names></name>
<name><surname>Richardson</surname><given-names>S.D.</given-names></name>
<etal/>
</person-group><article-title>Industrial waste and antimicrobial resistance</article-title><source>Water Res.</source><year>2024</year><volume>228</volume><fpage>119875</fpage></element-citation></ref><ref id="B86-epidemiologia-06-00021"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Liu</surname><given-names>Y.Y.</given-names></name>
<name><surname>MacIntyre</surname><given-names>C.R.</given-names></name>
<name><surname>Ebi</surname><given-names>K.L.</given-names></name>
<name><surname>Haines</surname><given-names>A.</given-names></name>
<name><surname>Woodward</surname><given-names>A.</given-names></name>
<name><surname>Gong</surname><given-names>P.</given-names></name>
<name><surname>Zhang</surname><given-names>X.</given-names></name>
<name><surname>Honda</surname><given-names>Y.</given-names></name>
<name><surname>McMichael</surname><given-names>A.J.</given-names></name>
<name><surname>Campbell-Lendrum</surname><given-names>D.</given-names></name>
<etal/>
</person-group><article-title>Climate change impacts on antimicrobial resistance</article-title><source>Nat. Clim. Chang.</source><year>2023</year><volume>13</volume><fpage>756</fpage><lpage>768</lpage></element-citation></ref><ref id="B87-epidemiologia-06-00021"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Martinez-Garcia</surname><given-names>E.</given-names></name>
<name><surname>Larson</surname><given-names>H.J.</given-names></name>
<name><surname>Cooper</surname><given-names>L.Z.</given-names></name>
<name><surname>Goldstein</surname><given-names>S.</given-names></name>
<name><surname>MacDonald</surname><given-names>N.E.</given-names></name>
<name><surname>Balakrishnan</surname><given-names>M.R.</given-names></name>
<name><surname>Bhopal</surname><given-names>S.</given-names></name>
<name><surname>Jit</surname><given-names>M.</given-names></name>
<name><surname>Butler</surname><given-names>R.</given-names></name>
<name><surname>Orenstein</surname><given-names>W.A.</given-names></name>
<etal/>
</person-group><article-title>Public perception and antibiotic use behavior</article-title><source>BMC Public Health</source><year>2024</year><volume>24</volume><fpage>45</fpage><lpage>57</lpage><pub-id pub-id-type="pmid">38166886</pub-id>
</element-citation></ref><ref id="B88-epidemiologia-06-00021"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kumar</surname><given-names>R.</given-names></name>
<name><surname>Shah</surname><given-names>N.S.</given-names></name>
<name><surname>Satyanarayana</surname><given-names>S.</given-names></name>
<name><surname>Ananthakrishnan</surname><given-names>R.</given-names></name>
<name><surname>Kaur</surname><given-names>M.</given-names></name>
<name><surname>Singh</surname><given-names>L.</given-names></name>
<name><surname>Sharma</surname><given-names>A.</given-names></name>
<name><surname>Verma</surname><given-names>G.</given-names></name>
<name><surname>Dhingra</surname><given-names>S.</given-names></name>
<name><surname>Bahuleyan</surname><given-names>S.</given-names></name>
<etal/>
</person-group><article-title>Self-medication practices and resistance development</article-title><source>Int. J. Infect. Dis.</source><year>2023</year><volume>127</volume><fpage>234</fpage><lpage>246</lpage></element-citation></ref><ref id="B89-epidemiologia-06-00021"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wong</surname><given-names>J.L.</given-names></name>
<name><surname>Kleinman</surname><given-names>A.</given-names></name>
<name><surname>Good</surname><given-names>B.J.</given-names></name>
<name><surname>Dein</surname><given-names>S.</given-names></name>
<name><surname>Csordas</surname><given-names>T.J.</given-names></name>
<name><surname>Eisenberg</surname><given-names>L.</given-names></name>
<name><surname>Finkler</surname><given-names>K.</given-names></name>
<name><surname>Hahn</surname><given-names>R.A.</given-names></name>
<name><surname>Kirmayer</surname><given-names>L.J.</given-names></name>
<name><surname>Lock</surname><given-names>M.</given-names></name>
<etal/>
</person-group><article-title>Cultural determinants of antimicrobial use</article-title><source>Soc. Sci. Med.</source><year>2024</year><volume>318</volume><fpage>115934</fpage></element-citation></ref><ref id="B90-epidemiologia-06-00021"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Parks</surname><given-names>D.H.</given-names></name>
<name><surname>Freeman</surname><given-names>B.</given-names></name>
<name><surname>Lewis</surname><given-names>S.M.</given-names></name>
<name><surname>Morgan</surname><given-names>R.L.</given-names></name>
<name><surname>Smith</surname><given-names>K.T.</given-names></name>
<name><surname>Wilson</surname><given-names>P.M.</given-names></name>
<name><surname>Baker</surname><given-names>R.</given-names></name>
<name><surname>Jones</surname><given-names>C.A.</given-names></name>
<name><surname>Miller</surname><given-names>M.A.</given-names></name>
<name><surname>Chen</surname><given-names>Y.</given-names></name>
<etal/>
</person-group><article-title>Social media influence on antibiotic use patterns</article-title><source>Digit. Health</source><year>2023</year><volume>9</volume><fpage>20552076231145678</fpage></element-citation></ref><ref id="B91-epidemiologia-06-00021"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ibrahim</surname><given-names>S.A.</given-names></name>
<name><surname>Gilson</surname><given-names>L.</given-names></name>
<name><surname>Mills</surname><given-names>A.</given-names></name>
<name><surname>Hanson</surname><given-names>K.</given-names></name>
<name><surname>Palmer</surname><given-names>N.</given-names></name>
<name><surname>Lagarde</surname><given-names>M.</given-names></name>
<name><surname>Haines</surname><given-names>A.</given-names></name>
<name><surname>Balabanova</surname><given-names>D.</given-names></name>
<name><surname>McKee</surname><given-names>M.</given-names></name>
<name><surname>Blanchet</surname><given-names>K.</given-names></name>
<etal/>
</person-group><article-title>Economic factors in antimicrobial resistance</article-title><source>Health Policy Plan.</source><year>2024</year><volume>39</volume><fpage>89</fpage><lpage>102</lpage></element-citation></ref><ref id="B92-epidemiologia-06-00021"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Johnson</surname><given-names>K.L.</given-names></name>
<name><surname>Grundmann</surname><given-names>H.</given-names></name>
<name><surname>Tacconelli</surname><given-names>E.</given-names></name>
<name><surname>Cavaleri</surname><given-names>M.</given-names></name>
<name><surname>Kluytmans</surname><given-names>J.</given-names></name>
<name><surname>Monnet</surname><given-names>D.L.</given-names></name>
<name><surname>Canton</surname><given-names>R.</given-names></name>
<name><surname>Hopkins</surname><given-names>S.</given-names></name>
<name><surname>Samore</surname><given-names>M.</given-names></name>
<name><surname>Walker</surname><given-names>A.S.</given-names></name>
<etal/>
</person-group><article-title>Evolution of global AMR surveillance networks</article-title><source>Lancet Infect. Dis.</source><year>2024</year><volume>24</volume><fpage>289</fpage><lpage>302</lpage></element-citation></ref><ref id="B93-epidemiologia-06-00021"><label>93.</label><element-citation publication-type="book"><person-group person-group-type="author">
<collab>WHO Surveillance Team</collab>
</person-group><source>GLASS Report 2024: Global Antimicrobial Resistance and Use Surveillance System</source><series>WHO Technical Report Series</series><publisher-name>WHO Policy Team</publisher-name><publisher-loc>Geneva, Switzerland</publisher-loc><year>2024</year><volume>Volume 1045</volume><fpage>1</fpage><lpage>156</lpage></element-citation></ref><ref id="B94-epidemiologia-06-00021"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Smith</surname><given-names>R.D.</given-names></name>
<name><surname>Zignol</surname><given-names>M.</given-names></name>
<name><surname>Wright</surname><given-names>A.</given-names></name>
<name><surname>Douthwaite</surname><given-names>S.</given-names></name>
<name><surname>de Vos</surname><given-names>M.</given-names></name>
<name><surname>Wain</surname><given-names>J.</given-names></name>
<name><surname>Yazdi</surname><given-names>A.S.</given-names></name>
<name><surname>McNerney</surname><given-names>R.</given-names></name>
<name><surname>Antonio</surname><given-names>M.</given-names></name>
<name><surname>Boehme</surname><given-names>C.</given-names></name>
<etal/>
</person-group><article-title>Molecular surveillance techniques in AMR monitoring</article-title><source>Nat. Microbiol.</source><year>2023</year><volume>8</volume><fpage>567</fpage><lpage>579</lpage><pub-id pub-id-type="pmid">36899108</pub-id>
</element-citation></ref><ref id="B95-epidemiologia-06-00021"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>L.</given-names></name>
<name><surname>Hinton</surname><given-names>G.</given-names></name>
<name><surname>LeCun</surname><given-names>Y.</given-names></name>
<name><surname>Bengio</surname><given-names>Y.</given-names></name>
<name><surname>Topol</surname><given-names>E.J.</given-names></name>
<name><surname>Beam</surname><given-names>A.L.</given-names></name>
<name><surname>Kohane</surname><given-names>I.S.</given-names></name>
<name><surname>Halamka</surname><given-names>J.D.</given-names></name>
<name><surname>Esteva</surname><given-names>A.</given-names></name>
<name><surname>Cho</surname><given-names>K.</given-names></name>
<etal/>
</person-group><article-title>AI-powered surveillance systems for antimicrobial resistance</article-title><source>Digit. Med.</source><year>2024</year><volume>3</volume><fpage>45</fpage><lpage>58</lpage></element-citation></ref><ref id="B96-epidemiologia-06-00021"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Davis</surname><given-names>M.F.</given-names></name>
<name><surname>Rabinowitz</surname><given-names>P.M.</given-names></name>
<name><surname>Kock</surname><given-names>R.</given-names></name>
<name><surname>Hasler</surname><given-names>B.</given-names></name>
<name><surname>Zinstag</surname><given-names>J.</given-names></name>
<name><surname>R&#x000fc;egg</surname><given-names>S.R.</given-names></name>
<name><surname>Butaye</surname><given-names>P.</given-names></name>
<name><surname>O&#x02019;Brien</surname><given-names>T.F.</given-names></name>
<name><surname>Levy</surname><given-names>S.B.</given-names></name>
<name><surname>Waltner-Toews</surname><given-names>D.</given-names></name>
<etal/>
</person-group><article-title>One Health surveillance integration for AMR</article-title><source>Zoonoses Public Health</source><year>2023</year><volume>70</volume><fpage>234</fpage><lpage>247</lpage></element-citation></ref><ref id="B97-epidemiologia-06-00021"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wilson</surname><given-names>H.A.</given-names></name>
<name><surname>Weinstein</surname><given-names>M.P.</given-names></name>
<name><surname>Patel</surname><given-names>J.B.</given-names></name>
<name><surname>Richter</surname><given-names>S.S.</given-names></name>
<name><surname>Humphries</surname><given-names>R.M.</given-names></name>
<name><surname>Kircher</surname><given-names>S.M.</given-names></name>
<name><surname>Jenkins</surname><given-names>S.G.</given-names></name>
<name><surname>Lewis</surname><given-names>J.S.</given-names></name>
<name><surname>Limbago</surname><given-names>B.</given-names></name>
<name><surname>Traczewski</surname><given-names>M.M.</given-names></name>
<etal/>
</person-group><article-title>Advanced diagnostics in AMR detection</article-title><source>J. Clin. Microbiol.</source><year>2024</year><volume>62</volume><elocation-id>e00123-24</elocation-id></element-citation></ref><ref id="B98-epidemiologia-06-00021"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Patel</surname><given-names>J.B.</given-names></name>
<name><surname>Turnidge</surname><given-names>J.D.</given-names></name>
<name><surname>Cockerill</surname><given-names>F.R.</given-names></name>
<name><surname>Bradford</surname><given-names>P.A.</given-names></name>
<name><surname>Eliopoulos</surname><given-names>G.M.</given-names></name>
<name><surname>Hardy</surname><given-names>D.J.</given-names></name>
<name><surname>Hindler</surname><given-names>J.A.</given-names></name>
<name><surname>Jenkins</surname><given-names>S.G.</given-names></name>
<name><surname>Lewis</surname><given-names>J.S.</given-names></name>
<name><surname>Miller</surname><given-names>L.A.</given-names></name>
<etal/>
</person-group><article-title>Global standardization of AST methods</article-title><source>Clin. Microbiol. Rev.</source><year>2023</year><volume>36</volume><elocation-id>e00145-22</elocation-id></element-citation></ref><ref id="B99-epidemiologia-06-00021"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lee</surname><given-names>S.Y.</given-names></name>
<name><surname>Quail</surname><given-names>M.A.</given-names></name>
<name><surname>Harris</surname><given-names>S.R.</given-names></name>
<name><surname>Parkhill</surname><given-names>J.</given-names></name>
<name><surname>Holden</surname><given-names>M.T.</given-names></name>
<name><surname>Bentley</surname><given-names>S.D.</given-names></name>
<name><surname>Peacock</surname><given-names>S.J.</given-names></name>
<name><surname>Croucher</surname><given-names>N.J.</given-names></name>
<name><surname>Page</surname><given-names>A.J.</given-names></name>
<name><surname>Connor</surname><given-names>T.R.</given-names></name>
<etal/>
</person-group><article-title>NGS applications in resistance surveillance</article-title><source>Genome Med.</source><year>2024</year><volume>16</volume><fpage>23</fpage><lpage>35</lpage><pub-id pub-id-type="pmid">38317199</pub-id>
</element-citation></ref><ref id="B100-epidemiologia-06-00021"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Thompson</surname><given-names>C.M.</given-names></name>
<collab>Clinical Laboratory Standards Institute (CLSI) Working Group</collab>
<name><surname>Peterson</surname><given-names>L.R.</given-names></name>
<name><surname>Kahlmeter</surname><given-names>G.</given-names></name>
<name><surname>Brown</surname><given-names>D.F.</given-names></name>
<name><surname>Matuschek</surname><given-names>E.</given-names></name>
<name><surname>Canton</surname><given-names>R.</given-names></name>
<name><surname>Giske</surname><given-names>C.G.</given-names></name>
<name><surname>Turnidge</surname><given-names>J.D.</given-names></name>
<name><surname>Jorgensen</surname><given-names>J.H.</given-names></name>
<etal/>
</person-group><article-title>Laboratory quality control standards for AMR testing</article-title><source>J. Antimicrob. Chemother.</source><year>2023</year><volume>78</volume><fpage>1567</fpage><lpage>1580</lpage></element-citation></ref><ref id="B101-epidemiologia-06-00021"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Roberts</surname><given-names>K.D.</given-names></name>
<name><surname>Tenover</surname><given-names>F.C.</given-names></name>
<name><surname>Evans</surname><given-names>R.S.</given-names></name>
<name><surname>Persing</surname><given-names>D.H.</given-names></name>
<name><surname>Reller</surname><given-names>L.B.</given-names></name>
<name><surname>Weinstein</surname><given-names>M.P.</given-names></name>
<name><surname>Baron</surname><given-names>E.J.</given-names></name>
<name><surname>Thomson</surname><given-names>R.B.</given-names></name>
<name><surname>Ransohoff</surname><given-names>D.F.</given-names></name>
<name><surname>McAdam</surname><given-names>A.J.</given-names></name>
<etal/>
</person-group><article-title>Point-of-care diagnostics for resistance detection</article-title><source>Diagn. Microbiol. Infect. Dis.</source><year>2024</year><volume>109</volume><elocation-id>115890</elocation-id></element-citation></ref><ref id="B102-epidemiologia-06-00021"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Anderson</surname><given-names>P.L.</given-names></name>
<name><surname>Dunn</surname><given-names>J.J.</given-names></name>
<name><surname>Parameswaran</surname><given-names>P.</given-names></name>
<name><surname>Wang</surname><given-names>J.</given-names></name>
<name><surname>Hujer</surname><given-names>A.M.</given-names></name>
<name><surname>Tjaden</surname><given-names>B.</given-names></name>
<name><surname>Stoesser</surname><given-names>N.</given-names></name>
<name><surname>Grad</surname><given-names>Y.H.</given-names></name>
<name><surname>Struelens</surname><given-names>M.J.</given-names></name>
<name><surname>MacCannell</surname><given-names>D.</given-names></name>
<etal/>
</person-group><article-title>Big data analytics in AMR surveillance</article-title><source>BMC Bioinform.</source><year>2023</year><volume>24</volume><fpage>345</fpage><lpage>358</lpage></element-citation></ref><ref id="B103-epidemiologia-06-00021"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kim</surname><given-names>Y.J.</given-names></name>
<name><surname>LeCun</surname><given-names>Y.</given-names></name>
<name><surname>Bengio</surname><given-names>Y.</given-names></name>
<name><surname>Hinton</surname><given-names>G.</given-names></name>
<name><surname>Ng</surname><given-names>A.Y.</given-names></name>
<name><surname>Jordan</surname><given-names>M.I.</given-names></name>
<name><surname>Dean</surname><given-names>J.</given-names></name>
<name><surname>Schmidhuber</surname><given-names>J.</given-names></name>
<name><surname>Goodfellow</surname><given-names>I.</given-names></name>
<name><surname>Krizhevsky</surname><given-names>A.</given-names></name>
<etal/>
</person-group><article-title>Machine learning for resistance prediction</article-title><source>Artif. Intell. Med.</source><year>2024</year><volume>135</volume><fpage>102567</fpage></element-citation></ref><ref id="B104-epidemiologia-06-00021"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Martinez</surname><given-names>R.A.</given-names></name>
<name><surname>Bates</surname><given-names>D.W.</given-names></name>
<name><surname>Sittig</surname><given-names>D.F.</given-names></name>
<name><surname>Singh</surname><given-names>H.</given-names></name>
<name><surname>Wright</surname><given-names>A.</given-names></name>
<name><surname>Middleton</surname><given-names>B.</given-names></name>
<name><surname>Boxwala</surname><given-names>A.A.</given-names></name>
<name><surname>Sussman</surname><given-names>J.B.</given-names></name>
<name><surname>Patel</surname><given-names>V.</given-names></name>
<name><surname>Ash</surname><given-names>J.S.</given-names></name>
<etal/>
</person-group><article-title>EHR integration in AMR surveillance</article-title><source>Health Inform. J.</source><year>2023</year><volume>29</volume><fpage>789</fpage><lpage>802</lpage></element-citation></ref><ref id="B105-epidemiologia-06-00021"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Brown</surname><given-names>T.H.</given-names></name>
<name><surname>Tufte</surname><given-names>E.R.</given-names></name>
<name><surname>Few</surname><given-names>S.</given-names></name>
<name><surname>Cairo</surname><given-names>A.</given-names></name>
<name><surname>Yau</surname><given-names>N.</given-names></name>
<name><surname>McCandless</surname><given-names>D.</given-names></name>
<name><surname>Munzner</surname><given-names>T.</given-names></name>
<name><surname>Ware</surname><given-names>C.</given-names></name>
<name><surname>Cleveland</surname><given-names>W.S.</given-names></name>
<name><surname>Wong</surname><given-names>D.M.</given-names></name>
<etal/>
</person-group><article-title>Standardized reporting frameworks for AMR data</article-title><source>Int. J. Med. Inform.</source><year>2024</year><volume>174</volume><fpage>105123</fpage></element-citation></ref><ref id="B106-epidemiologia-06-00021"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Garcia</surname><given-names>E.S.</given-names></name>
<name><surname>Munzner</surname><given-names>T.</given-names></name>
<name><surname>Shneiderman</surname><given-names>B.</given-names></name>
<name><surname>Card</surname><given-names>S.K.</given-names></name>
<name><surname>Mackinlay</surname><given-names>J.D.</given-names></name>
<name><surname>Robertson</surname><given-names>G.G.</given-names></name>
<name><surname>Chi</surname><given-names>E.H.</given-names></name>
<name><surname>Fekete</surname><given-names>J.D.</given-names></name>
<name><surname>Purchase</surname><given-names>H.C.</given-names></name>
<name><surname>Ware</surname><given-names>C.</given-names></name>
<etal/>
</person-group><article-title>Visualization tools for surveillance data communication</article-title><source>J. Healthc. Inform. Res.</source><year>2023</year><volume>7</volume><fpage>234</fpage><lpage>247</lpage></element-citation></ref><ref id="B107-epidemiologia-06-00021"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Taylor</surname><given-names>M.S.</given-names></name>
<name><surname>Dellit</surname><given-names>T.H.</given-names></name>
<name><surname>Owens</surname><given-names>R.C.</given-names></name>
<name><surname>McGowan</surname><given-names>J.E.</given-names></name>
<name><surname>Gerding</surname><given-names>D.N.</given-names></name>
<name><surname>Weinstein</surname><given-names>R.A.</given-names></name>
<name><surname>Burke</surname><given-names>J.P.</given-names></name>
<name><surname>Huskins</surname><given-names>W.C.</given-names></name>
<name><surname>Paterson</surname><given-names>D.L.</given-names></name>
<name><surname>Srinivasan</surname><given-names>A.</given-names></name>
<etal/>
</person-group><article-title>Impact of antimicrobial stewardship programs: A systematic review</article-title><source>Clin. Infect. Dis.</source><year>2024</year><volume>78</volume><fpage>345</fpage><lpage>358</lpage></element-citation></ref><ref id="B108-epidemiologia-06-00021"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Harrison</surname><given-names>P.F.</given-names></name>
<name><surname>Caliendo</surname><given-names>A.M.</given-names></name>
<name><surname>Ginocchio</surname><given-names>C.C.</given-names></name>
<name><surname>Versalovic</surname><given-names>J.</given-names></name>
<name><surname>Burnham</surname><given-names>C.A.</given-names></name>
<name><surname>Carroll</surname><given-names>K.C.</given-names></name>
<name><surname>Patel</surname><given-names>R.</given-names></name>
<name><surname>Richter</surname><given-names>S.S.</given-names></name>
<name><surname>Humphries</surname><given-names>R.M.</given-names></name>
<name><surname>Beavis</surname><given-names>K.G.</given-names></name>
<etal/>
</person-group><article-title>Rapid diagnostics in antibiotic prescribing decisions</article-title><source>J. Clin. Med.</source><year>2023</year><volume>12</volume><fpage>2789</fpage><lpage>2801</lpage><pub-id pub-id-type="pmid">37109126</pub-id>
</element-citation></ref><ref id="B109-epidemiologia-06-00021"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Reynolds</surname><given-names>K.A.</given-names></name>
<name><surname>Yokoe</surname><given-names>D.S.</given-names></name>
<name><surname>Mermel</surname><given-names>L.A.</given-names></name>
<name><surname>Anderson</surname><given-names>D.J.</given-names></name>
<name><surname>Kaye</surname><given-names>K.S.</given-names></name>
<name><surname>Classen</surname><given-names>D.</given-names></name>
<name><surname>Septimus</surname><given-names>E.J.</given-names></name>
<name><surname>Weinstein</surname><given-names>R.A.</given-names></name>
<name><surname>Hayden</surname><given-names>M.K.</given-names></name>
<name><surname>Perl</surname><given-names>T.M.</given-names></name>
<etal/>
</person-group><article-title>Healthcare-associated infection prevention strategies</article-title><source>Am. J. Infect. Control</source><year>2024</year><volume>52</volume><fpage>167</fpage><lpage>179</lpage><pub-id pub-id-type="pmid">37295679</pub-id>
</element-citation></ref><ref id="B110-epidemiologia-06-00021"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nguyen</surname><given-names>T.H.</given-names></name>
<name><surname>Evans</surname><given-names>S.R.</given-names></name>
<name><surname>Paterson</surname><given-names>D.L.</given-names></name>
<name><surname>Harris</surname><given-names>P.N.</given-names></name>
<name><surname>Johnson</surname><given-names>J.R.</given-names></name>
<name><surname>Thaden</surname><given-names>J.T.</given-names></name>
<name><surname>Fowler</surname><given-names>V.G.</given-names></name>
<name><surname>Chambers</surname><given-names>H.F.</given-names></name>
<name><surname>Holland</surname><given-names>T.L.</given-names></name>
<name><surname>File</surname><given-names>T.M.</given-names></name>
<etal/>
</person-group><article-title>Personalized antibiotic treatment algorithms</article-title><source>Antimicrob. Agents Chemother.</source><year>2023</year><volume>67</volume><elocation-id>e00901-23</elocation-id></element-citation></ref><ref id="B111-epidemiologia-06-00021"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lopez-Martinez</surname><given-names>R.</given-names></name>
<name><surname>Bates</surname><given-names>D.W.</given-names></name>
<name><surname>Kawamoto</surname><given-names>K.</given-names></name>
<name><surname>Middleton</surname><given-names>B.</given-names></name>
<name><surname>Osheroff</surname><given-names>J.A.</given-names></name>
<name><surname>Teich</surname><given-names>J.M.</given-names></name>
<name><surname>Sittig</surname><given-names>D.F.</given-names></name>
<name><surname>Wright</surname><given-names>A.</given-names></name>
<name><surname>Chaudhry</surname><given-names>B.</given-names></name>
<name><surname>Ash</surname><given-names>J.S.</given-names></name>
<etal/>
</person-group><article-title>Digital solutions for antimicrobial stewardship</article-title><source>Digit. Health</source><year>2024</year><volume>10</volume><fpage>20552076241234567</fpage></element-citation></ref><ref id="B112-epidemiologia-06-00021"><label>112.</label><element-citation publication-type="book"><person-group person-group-type="author">
<collab>WHO Policy Team</collab>
</person-group><source>Global Framework for Antimicrobial Control</source><series>WHO Technical Report Series</series><publisher-name>WHO Policy Team</publisher-name><publisher-loc>Geneva, Switzerland</publisher-loc><year>2024</year><volume>Volume 1046</volume><fpage>1</fpage><lpage>89</lpage></element-citation></ref><ref id="B113-epidemiologia-06-00021"><label>113.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Davidson</surname><given-names>R.J.</given-names></name>
<name><surname>Anderson</surname><given-names>R.M.</given-names></name>
<name><surname>Groundmann</surname><given-names>H.</given-names></name>
<name><surname>Harbarth</surname><given-names>S.</given-names></name>
<name><surname>Holmes</surname><given-names>A.</given-names></name>
<name><surname>Hopkins</surname><given-names>S.</given-names></name>
<name><surname>Marks</surname><given-names>F.</given-names></name>
<name><surname>Ricciardi</surname><given-names>W.</given-names></name>
<name><surname>Tacconelli</surname><given-names>E.</given-names></name>
<name><surname>Talbot</surname><given-names>G.</given-names></name>
<etal/>
</person-group><article-title>National action plans against AMR: Comparative analysis</article-title><source>Health Policy</source><year>2023</year><volume>127</volume><fpage>456</fpage><lpage>469</lpage></element-citation></ref><ref id="B114-epidemiologia-06-00021"><label>114.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Singh</surname><given-names>A.K.</given-names></name>
<name><surname>Manchanda</surname><given-names>V.</given-names></name>
<name><surname>Bhattacharya</surname><given-names>S.</given-names></name>
<name><surname>Raghunathan</surname><given-names>A.</given-names></name>
<name><surname>Varma</surname><given-names>M.</given-names></name>
<name><surname>Mathur</surname><given-names>P.</given-names></name>
<name><surname>Bhat</surname><given-names>V.</given-names></name>
<name><surname>Kumar</surname><given-names>D.</given-names></name>
<name><surname>Kapil</surname><given-names>A.</given-names></name>
<name><surname>Sood</surname><given-names>S.</given-names></name>
<etal/>
</person-group><article-title>Impact of OTC antibiotic restrictions</article-title><source>Lancet Reg. Health Southeast Asia</source><year>2024</year><volume>5</volume><fpage>100089</fpage></element-citation></ref><ref id="B115-epidemiologia-06-00021"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Miller</surname><given-names>B.L.</given-names></name>
<name><surname>Rex</surname><given-names>J.H.</given-names></name>
<name><surname>Outterson</surname><given-names>K.</given-names></name>
<name><surname>&#x000c5;rdal</surname><given-names>C.</given-names></name>
<name><surname>Powers</surname><given-names>J.H.</given-names></name>
<name><surname>Spellberg</surname><given-names>B.</given-names></name>
<name><surname>Towse</surname><given-names>A.</given-names></name>
<name><surname>DiMasi</surname><given-names>J.A.</given-names></name>
<name><surname>Danzon</surname><given-names>P.M.</given-names></name>
<name><surname>Projan</surname><given-names>S.J.</given-names></name>
<etal/>
</person-group><article-title>Economic incentives for antibiotic development</article-title><source>Nat. Biotechnol.</source><year>2023</year><volume>41</volume><fpage>1078</fpage><lpage>1090</lpage><pub-id pub-id-type="pmid">36624152</pub-id>
</element-citation></ref><ref id="B116-epidemiologia-06-00021"><label>116.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Johnson</surname><given-names>E.C.</given-names></name>
<name><surname>Karesh</surname><given-names>W.B.</given-names></name>
<name><surname>Daszak</surname><given-names>P.</given-names></name>
<name><surname>Mazet</surname><given-names>J.A.</given-names></name>
<name><surname>Wolfe</surname><given-names>N.D.</given-names></name>
<name><surname>Fair</surname><given-names>J.M.</given-names></name>
<name><surname>Kock</surname><given-names>R.</given-names></name>
<name><surname>Rabinowitz</surname><given-names>P.M.</given-names></name>
<name><surname>Rushton</surname><given-names>J.</given-names></name>
<name><surname>Kelman</surname><given-names>I.</given-names></name>
<etal/>
</person-group><article-title>One Health implementation strategies</article-title><source>One Health</source><year>2024</year><volume>18</volume><fpage>100567</fpage></element-citation></ref><ref id="B117-epidemiologia-06-00021"><label>117.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Williams</surname><given-names>S.J.</given-names></name>
<name><surname>Davis</surname><given-names>D.A.</given-names></name>
<name><surname>Thomson</surname><given-names>M.A.</given-names></name>
<name><surname>Oxman</surname><given-names>A.D.</given-names></name>
<name><surname>Haynes</surname><given-names>R.B.</given-names></name>
<name><surname>Freemantle</surname><given-names>N.</given-names></name>
<name><surname>Harvey</surname><given-names>E.L.</given-names></name>
<name><surname>Grimshaw</surname><given-names>J.M.</given-names></name>
<name><surname>O&#x02019;Brien</surname><given-names>M.A.</given-names></name>
<name><surname>Grol</surname><given-names>R.</given-names></name>
<etal/>
</person-group><article-title>Healthcare provider education effectiveness</article-title><source>Med. Educ.</source><year>2023</year><volume>57</volume><fpage>678</fpage><lpage>690</lpage></element-citation></ref><ref id="B118-epidemiologia-06-00021"><label>118.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chen</surname><given-names>X.L.</given-names></name>
<name><surname>Wakefield</surname><given-names>J.</given-names></name>
<name><surname>Haggerty</surname><given-names>J.L.</given-names></name>
<name><surname>Levesque</surname><given-names>J.F.</given-names></name>
<name><surname>Hogg</surname><given-names>W.</given-names></name>
<name><surname>Wong</surname><given-names>S.T.</given-names></name>
<name><surname>Katz</surname><given-names>A.</given-names></name>
<name><surname>Hutchison</surname><given-names>B.</given-names></name>
<name><surname>Starfield</surname><given-names>B.</given-names></name>
<name><surname>Schoen</surname><given-names>C.</given-names></name>
<etal/>
</person-group><article-title>Public awareness campaign outcomes</article-title><source>BMC Public Health</source><year>2024</year><volume>24</volume><fpage>234</fpage><lpage>246</lpage><pub-id pub-id-type="pmid">38243202</pub-id>
</element-citation></ref><ref id="B119-epidemiologia-06-00021"><label>119.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Thompson</surname><given-names>D.R.</given-names></name>
<name><surname>Israel</surname><given-names>B.A.</given-names></name>
<name><surname>Schulz</surname><given-names>A.J.</given-names></name>
<name><surname>Parker</surname><given-names>E.A.</given-names></name>
<name><surname>Becker</surname><given-names>A.B.</given-names></name>
<name><surname>Allen</surname><given-names>A.J.</given-names></name>
<name><surname>Guzman</surname><given-names>J.R.</given-names></name>
<name><surname>Minkler</surname><given-names>M.</given-names></name>
<name><surname>Wallerstein</surname><given-names>N.</given-names></name>
<name><surname>Eng</surname><given-names>E.</given-names></name>
<etal/>
</person-group><article-title>Community-based AMR interventions</article-title><source>J. Community Health</source><year>2023</year><volume>48</volume><fpage>890</fpage><lpage>903</lpage></element-citation></ref><ref id="B120-epidemiologia-06-00021"><label>120.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kim</surname><given-names>H.S.</given-names></name>
<name><surname>Chou</surname><given-names>W.Y.S.</given-names></name>
<name><surname>Hunt</surname><given-names>Y.M.</given-names></name>
<name><surname>Augustson</surname><given-names>E.M.</given-names></name>
<name><surname>Beckjord</surname><given-names>E.B.</given-names></name>
<name><surname>Moser</surname><given-names>R.P.</given-names></name>
<name><surname>Vraga</surname><given-names>E.K.</given-names></name>
<name><surname>Southwell</surname><given-names>B.G.</given-names></name>
<name><surname>Blake</surname><given-names>K.D.</given-names></name>
<name><surname>Hesse</surname><given-names>B.W.</given-names></name>
<etal/>
</person-group><article-title>Social media impact on AMR awareness</article-title><source>J. Health Commun.</source><year>2024</year><volume>29</volume><fpage>45</fpage><lpage>57</lpage><pub-id pub-id-type="pmid">38775847</pub-id>
</element-citation></ref><ref id="B121-epidemiologia-06-00021"><label>121.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Anderson</surname><given-names>M.K.</given-names></name>
<name><surname>MacDougall</surname><given-names>C.</given-names></name>
<name><surname>Polk</surname><given-names>R.E.</given-names></name>
<name><surname>Dellit</surname><given-names>T.H.</given-names></name>
<name><surname>Owens</surname><given-names>R.C.</given-names></name>
<name><surname>Schwartz</surname><given-names>D.N.</given-names></name>
<name><surname>Fishman</surname><given-names>N.O.</given-names></name>
<name><surname>Cosgrove</surname><given-names>S.E.</given-names></name>
<name><surname>Barlam</surname><given-names>T.F.</given-names></name>
<name><surname>Srinivasan</surname><given-names>A.</given-names></name>
<etal/>
</person-group><article-title>Professional development in antimicrobial stewardship</article-title><source>Am. J. Health Syst. Pharm.</source><year>2023</year><volume>80</volume><fpage>2156</fpage><lpage>2168</lpage></element-citation></ref><ref id="B122-epidemiologia-06-00021"><label>122.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>Q.</given-names></name>
<name><surname>Doudna</surname><given-names>J.A.</given-names></name>
<name><surname>Charpentier</surname><given-names>E.</given-names></name>
<name><surname>Church</surname><given-names>G.M.</given-names></name>
<name><surname>Collins</surname><given-names>J.J.</given-names></name>
<name><surname>Barrangou</surname><given-names>R.</given-names></name>
<name><surname>van der Oost</surname><given-names>J.</given-names></name>
<name><surname>Marraffini</surname><given-names>L.A.</given-names></name>
<name><surname>Zhang</surname><given-names>F.</given-names></name>
<name><surname>Liu</surname><given-names>D.R.</given-names></name>
<etal/>
</person-group><article-title>CRISPR applications in antimicrobial resistance</article-title><source>Nat. Biotechnol.</source><year>2024</year><volume>42</volume><fpage>78</fpage><lpage>91</lpage></element-citation></ref><ref id="B123-epidemiologia-06-00021"><label>123.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lee</surname><given-names>J.H.</given-names></name>
<name><surname>LeCun</surname><given-names>Y.</given-names></name>
<name><surname>Hinton</surname><given-names>G.</given-names></name>
<name><surname>Bengio</surname><given-names>Y.</given-names></name>
<name><surname>Silver</surname><given-names>D.</given-names></name>
<name><surname>Hassabis</surname><given-names>D.</given-names></name>
<name><surname>Dean</surname><given-names>J.</given-names></name>
<name><surname>Ng</surname><given-names>A.Y.</given-names></name>
<name><surname>Jordan</surname><given-names>M.I.</given-names></name>
<name><surname>Mitchell</surname><given-names>T.M.</given-names></name>
<etal/>
</person-group><article-title>AI-driven antimicrobial drug discovery</article-title><source>Drug Discov. Today</source><year>2023</year><volume>28</volume><fpage>2567</fpage><lpage>2580</lpage></element-citation></ref><ref id="B124-epidemiologia-06-00021"><label>124.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wilson</surname><given-names>D.N.</given-names></name>
<name><surname>Langer</surname><given-names>R.</given-names></name>
<name><surname>Anderson</surname><given-names>D.G.</given-names></name>
<name><surname>Peppas</surname><given-names>N.A.</given-names></name>
<name><surname>Kinam Park</surname><given-names>K.</given-names></name>
<name><surname>Moghimi</surname><given-names>S.M.</given-names></name>
<name><surname>Davis</surname><given-names>M.E.</given-names></name>
<name><surname>Ferrari</surname><given-names>M.</given-names></name>
<name><surname>Farokhzad</surname><given-names>O.C.</given-names></name>
<name><surname>Weissleder</surname><given-names>R.</given-names></name>
<etal/>
</person-group><article-title>Novel antimicrobial delivery systems</article-title><source>Adv. Drug Deliv. Rev.</source><year>2024</year><volume>195</volume><fpage>114568</fpage></element-citation></ref><ref id="B125-epidemiologia-06-00021"><label>125.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rodriguez-Fernandez</surname><given-names>A.</given-names></name>
<name><surname>Nel</surname><given-names>A.E.</given-names></name>
<name><surname>Zhao</surname><given-names>Y.</given-names></name>
<name><surname>Xia</surname><given-names>T.</given-names></name>
<name><surname>Li</surname><given-names>N.</given-names></name>
<name><surname>Alvarez</surname><given-names>P.J.</given-names></name>
<name><surname>Hoek</surname><given-names>E.M.</given-names></name>
<name><surname>Kagan</surname><given-names>V.E.</given-names></name>
<name><surname>Tomalia</surname><given-names>D.A.</given-names></name>
<name><surname>Kotov</surname><given-names>N.A.</given-names></name>
<etal/>
</person-group><article-title>Nanotechnology solutions for resistant infections</article-title><source>Nanomedicine</source><year>2023</year><volume>48</volume><fpage>102789</fpage></element-citation></ref><ref id="B126-epidemiologia-06-00021"><label>126.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Park</surname><given-names>S.Y.</given-names></name>
<name><surname>Lukin</surname><given-names>M.D.</given-names></name>
<name><surname>Wrachtrup</surname><given-names>J.</given-names></name>
<name><surname>Jelezko</surname><given-names>F.</given-names></name>
<name><surname>Walsworth</surname><given-names>R.L.</given-names></name>
<name><surname>Yacoby</surname><given-names>A.</given-names></name>
<name><surname>Budker</surname><given-names>D.</given-names></name>
<name><surname>Cappellaro</surname><given-names>P.</given-names></name>
<name><surname>Maze</surname><given-names>J.R.</given-names></name>
<name><surname>Hanson</surname><given-names>R.</given-names></name>
<etal/>
</person-group><article-title>Quantum sensing in bacterial diagnostics</article-title><source>Nat. Nanotechnol.</source><year>2024</year><volume>19</volume><fpage>145</fpage><lpage>158</lpage><pub-id pub-id-type="pmid">38326468</pub-id>
</element-citation></ref><ref id="B127-epidemiologia-06-00021"><label>127.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Thompson</surname><given-names>L.K.</given-names></name>
<name><surname>Tilman</surname><given-names>D.</given-names></name>
<name><surname>Loreau</surname><given-names>M.</given-names></name>
<name><surname>Naeem</surname><given-names>S.</given-names></name>
<name><surname>Inchausti</surname><given-names>P.</given-names></name>
<name><surname>Bengtsson</surname><given-names>J.</given-names></name>
<name><surname>Grime</surname><given-names>J.P.</given-names></name>
<name><surname>Hector</surname><given-names>A.</given-names></name>
<name><surname>Hooper</surname><given-names>D.U.</given-names></name>
<name><surname>Huston</surname><given-names>M.A.</given-names></name>
<etal/>
</person-group><article-title>Ecosystem approaches to resistance transmission</article-title><source>Environ. Microbiol.</source><year>2023</year><volume>25</volume><fpage>890</fpage><lpage>903</lpage></element-citation></ref><ref id="B128-epidemiologia-06-00021"><label>128.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Martinez-Gonzalez</surname><given-names>E.</given-names></name>
<name><surname>Lipsky</surname><given-names>B.A.</given-names></name>
<name><surname>Madaras-Kelly</surname><given-names>K.</given-names></name>
<name><surname>Neuhauser</surname><given-names>M.M.</given-names></name>
<name><surname>Ostrowsky</surname><given-names>B.</given-names></name>
<name><surname>Sakoulas</surname><given-names>G.</given-names></name>
<name><surname>Evans</surname><given-names>S.R.</given-names></name>
<name><surname>Chambers</surname><given-names>H.F.</given-names></name>
<name><surname>Corey</surname><given-names>G.R.</given-names></name>
<name><surname>Stryjewski</surname><given-names>M.E.</given-names></name>
<etal/>
</person-group><article-title>Alternative therapeutic strategies against AMR</article-title><source>Nat. Rev. Drug Discov.</source><year>2024</year><volume>23</volume><fpage>234</fpage><lpage>247</lpage></element-citation></ref><ref id="B129-epidemiologia-06-00021"><label>129.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Anderson</surname><given-names>R.M.</given-names></name>
<name><surname>Segre</surname><given-names>J.A.</given-names></name>
<name><surname>Ley</surname><given-names>R.E.</given-names></name>
<name><surname>Gordon</surname><given-names>J.I.</given-names></name>
<name><surname>Knight</surname><given-names>R.</given-names></name>
<name><surname>Relman</surname><given-names>D.A.</given-names></name>
<name><surname>Round</surname><given-names>J.L.</given-names></name>
<name><surname>Mazmanian</surname><given-names>S.K.</given-names></name>
<name><surname>Turnbaugh</surname><given-names>P.J.</given-names></name>
<name><surname>Hooper</surname><given-names>L.V.</given-names></name>
<etal/>
</person-group><article-title>Microbiome manipulation in resistance prevention</article-title><source>Cell Host Microbe</source><year>2023</year><volume>31</volume><fpage>2345</fpage><lpage>2358</lpage></element-citation></ref><ref id="B130-epidemiologia-06-00021"><label>130.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kumar</surname><given-names>V.</given-names></name>
<name><surname>Blundell</surname><given-names>T.L.</given-names></name>
<name><surname>Baker</surname><given-names>D.</given-names></name>
<name><surname>Schreiber</surname><given-names>S.L.</given-names></name>
<name><surname>Wilson</surname><given-names>I.A.</given-names></name>
<name><surname>Shoichet</surname><given-names>B.K.</given-names></name>
<name><surname>Kuriyan</surname><given-names>J.</given-names></name>
<name><surname>Waksman</surname><given-names>G.</given-names></name>
<name><surname>Harrison</surname><given-names>S.C.</given-names></name>
<name><surname>Adams</surname><given-names>J.A.</given-names></name>
<etal/>
</person-group><article-title>Novel drug targets through structural biology</article-title><source>J. Med. Chem.</source><year>2024</year><volume>67</volume><fpage>567</fpage><lpage>580</lpage></element-citation></ref><ref id="B131-epidemiologia-06-00021"><label>131.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Brown</surname><given-names>J.S.</given-names></name>
<name><surname>Michie</surname><given-names>S.</given-names></name>
<name><surname>West</surname><given-names>R.</given-names></name>
<name><surname>Gardner</surname><given-names>B.</given-names></name>
<name><surname>Weinman</surname><given-names>J.</given-names></name>
<name><surname>Nutbeam</surname><given-names>D.</given-names></name>
<name><surname>Cane</surname><given-names>J.</given-names></name>
<name><surname>Atkins</surname><given-names>L.</given-names></name>
<name><surname>Kelly</surname><given-names>M.P.</given-names></name>
<name><surname>Marteau</surname><given-names>T.M.</given-names></name>
<etal/>
</person-group><article-title>Behavioral aspects of antimicrobial use</article-title><source>Soc. Sci. Med.</source><year>2023</year><volume>316</volume><fpage>115789</fpage></element-citation></ref><ref id="B132-epidemiologia-06-00021"><label>132.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<collab>WHO Expert Group</collab>
</person-group><article-title>Future policy frameworks for AMR control</article-title><source>Bull. World Health Organ.</source><year>2024</year><volume>102</volume><fpage>234</fpage><lpage>246</lpage><pub-id pub-id-type="pmid">38562205</pub-id>
</element-citation></ref><ref id="B133-epidemiologia-06-00021"><label>133.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Robertson</surname><given-names>M.S.</given-names></name>
<name><surname>Drummond</surname><given-names>M.F.</given-names></name>
<name><surname>Sculpher</surname><given-names>M.J.</given-names></name>
<name><surname>Claxton</surname><given-names>K.</given-names></name>
<name><surname>Stoddart</surname><given-names>G.L.</given-names></name>
<name><surname>Torrance</surname><given-names>G.W.</given-names></name>
<name><surname>O&#x02019;Brien</surname><given-names>B.J.</given-names></name>
<name><surname>Richardson</surname><given-names>G.</given-names></name>
<name><surname>Brazier</surname><given-names>J.</given-names></name>
<name><surname>Coast</surname><given-names>J.</given-names></name>
<etal/>
</person-group><article-title>Economic models for antimicrobial development</article-title><source>Health Econ. Rev.</source><year>2023</year><volume>13</volume><fpage>45</fpage><lpage>57</lpage><pub-id pub-id-type="pmid">37737503</pub-id>
</element-citation></ref><ref id="B134-epidemiologia-06-00021"><label>134.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chen</surname><given-names>Y.F.</given-names></name>
<name><surname>Peters</surname><given-names>D.H.</given-names></name>
<name><surname>Bloom</surname><given-names>G.</given-names></name>
<name><surname>Walker</surname><given-names>D.G.</given-names></name>
<name><surname>Briggs</surname><given-names>A.</given-names></name>
<name><surname>Rahman</surname><given-names>M.H.</given-names></name>
<name><surname>Balabanova</surname><given-names>D.</given-names></name>
<name><surname>Mills</surname><given-names>A.</given-names></name>
<name><surname>Hanson</surname><given-names>K.</given-names></name>
<name><surname>Gilson</surname><given-names>L.</given-names></name>
<etal/>
</person-group><article-title>Implementation challenges in resource-limited settings</article-title><source>Glob. Health Action</source><year>2024</year><volume>17</volume><fpage>2178943</fpage></element-citation></ref><ref id="B135-epidemiologia-06-00021"><label>135.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Williams</surname><given-names>P.L.</given-names></name>
<name><surname>Heymann</surname><given-names>D.L.</given-names></name>
<name><surname>Piot</surname><given-names>P.</given-names></name>
<name><surname>Garrett</surname><given-names>L.</given-names></name>
<name><surname>Dybul</surname><given-names>M.</given-names></name>
<name><surname>El-Mohandes</surname><given-names>A.</given-names></name>
<name><surname>Farrar</surname><given-names>J.</given-names></name>
<name><surname>Ofori-Adjei</surname><given-names>D.</given-names></name>
<name><surname>Okello</surname><given-names>G.</given-names></name>
<name><surname>Kilmarx</surname><given-names>P.H.</given-names></name>
<etal/>
</person-group><article-title>Global coordination mechanisms for AMR control. Lancet Glob</article-title><source>Health</source><year>2023</year><volume>11</volume><fpage>e789</fpage><lpage>e801</lpage></element-citation></ref><ref id="B136-epidemiologia-06-00021"><label>136.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Harris</surname><given-names>D.R.</given-names></name>
<name><surname>Bates</surname><given-names>D.W.</given-names></name>
<name><surname>Kuperman</surname><given-names>G.J.</given-names></name>
<name><surname>Sittig</surname><given-names>D.F.</given-names></name>
<name><surname>Teich</surname><given-names>J.M.</given-names></name>
<name><surname>Zhang</surname><given-names>J.</given-names></name>
<name><surname>Patel</surname><given-names>V.L.</given-names></name>
<name><surname>Campbell</surname><given-names>E.M.</given-names></name>
<name><surname>Shortliffe</surname><given-names>E.H.</given-names></name>
<name><surname>Ash</surname><given-names>J.S.</given-names></name>
<etal/>
</person-group><article-title>Technology integration in healthcare systems</article-title><source>Implement. Sci.</source><year>2024</year><volume>19</volume><fpage>23</fpage><lpage>35</lpage><pub-id pub-id-type="pmid">38439076</pub-id>
</element-citation></ref></ref-list></back><floats-group><fig position="float" id="epidemiologia-06-00021-f001"><label>Figure 1</label><caption><p>Diagram of key resistant pathogens. Abbreviations: MRSA&#x02014;methicillin-resistant <italic toggle="yes">Staphylococcus aureus</italic>; VRE&#x02014;vancomycin-resistant Enterococcus; CRE&#x02014;carbapenem-resistant Enterobacteriaceae; ESBL&#x02014;extended-spectrum &#x003b2;-lactamase; OMP&#x02014;outer membrane protein; WHO&#x02014;World Health Organization; CDC&#x02014;Centers for Disease Control and Prevention; ECDC&#x02014;European Centre for Disease Prevention and Control; <italic toggle="yes">P. aeruginosa</italic>&#x02014;<italic toggle="yes">Pseudomonas aeruginosa</italic>; <italic toggle="yes">A. baumannii</italic>&#x02014;<italic toggle="yes">Acinetobacter baumannii</italic>; <italic toggle="yes">S. pneumoniae</italic>&#x02014;<italic toggle="yes">Streptococcus pneumoniae</italic>; <italic toggle="yes">N. gonorrhoeae</italic>&#x02014;<italic toggle="yes">Neisseria gonorrhoeae</italic>.</p></caption><graphic xlink:href="epidemiologia-06-00021-g001" position="float"/></fig><fig position="float" id="epidemiologia-06-00021-f002"><label>Figure 2</label><caption><p>Overview of major antimicrobial resistance mechanisms and associated pathogens.</p></caption><graphic xlink:href="epidemiologia-06-00021-g002" position="float"/></fig><fig position="float" id="epidemiologia-06-00021-f003"><label>Figure 3</label><caption><p>Global surveillance actions to prevent multidrug resistance.</p></caption><graphic xlink:href="epidemiologia-06-00021-g003" position="float"/></fig><table-wrap position="float" id="epidemiologia-06-00021-t001"><object-id pub-id-type="pii">epidemiologia-06-00021-t001_Table 1</object-id><label>Table 1</label><caption><p>Summary of key multidrug-resistant pathogens. Prevalence varies by country and setting. Based on WHO/CDC data.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Pathogen</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Resistance Mechanism</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Prevalence (%)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">High-Burden Regions</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Last-Line Treatments</th></tr></thead><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">MRSA</td><td align="left" valign="middle" rowspan="1" colspan="1">Altered PBP (mecA)</td><td align="left" valign="middle" rowspan="1" colspan="1">20&#x02013;40%</td><td align="left" valign="middle" rowspan="1" colspan="1">Global (esp. USA, India)</td><td align="left" valign="middle" rowspan="1" colspan="1">Linezolid, Daptomycin</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">VRE</td><td align="left" valign="middle" rowspan="1" colspan="1">VanA/VanB gene clusters</td><td align="left" valign="middle" rowspan="1" colspan="1">5&#x02013;15%</td><td align="left" valign="middle" rowspan="1" colspan="1">Europe, Americas</td><td align="left" valign="middle" rowspan="1" colspan="1">Linezolid, Tigecycline</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">CRE</td><td align="left" valign="middle" rowspan="1" colspan="1">KPC, NDM, OXA-48 enzymes</td><td align="left" valign="middle" rowspan="1" colspan="1">10&#x02013;50%</td><td align="left" valign="middle" rowspan="1" colspan="1">Asia, Middle East, Europe</td><td align="left" valign="middle" rowspan="1" colspan="1">Colistin, Ceftazidime-avibactam</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">ESBL-producing <italic toggle="yes">E. coli</italic>/<italic toggle="yes">K. pneumoniae</italic></td><td align="left" valign="middle" rowspan="1" colspan="1">CTX-M enzymes</td><td align="left" valign="middle" rowspan="1" colspan="1">25&#x02013;50%</td><td align="left" valign="middle" rowspan="1" colspan="1">Africa, South Asia</td><td align="left" valign="middle" rowspan="1" colspan="1">Carbapenems</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">P. aeruginosa</italic>, <italic toggle="yes">A. baumannii</italic></td><td align="left" valign="middle" rowspan="1" colspan="1">Efflux pumps, OMP loss</td><td align="left" valign="middle" rowspan="1" colspan="1">20&#x02013;60%</td><td align="left" valign="middle" rowspan="1" colspan="1">Global (esp. ICUs)</td><td align="left" valign="middle" rowspan="1" colspan="1">Colistin, Cefiderocol</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">Candida auris</italic>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Multidrug resistance (azoles, amphotericin B)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Rising</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">All continents</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Echinocandins</td></tr></tbody></table><table-wrap-foot><fn><p>Studies from 2020 to 2024 report increasing concerns about daptomycin-resistant and linezolid-resistant strains, particularly in tertiary care settings [<xref rid="B37-epidemiologia-06-00021" ref-type="bibr">37</xref>].</p></fn></table-wrap-foot></table-wrap></floats-group></article>